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CHAPTER 1 
GENERAL INTRODUCTION 
1. HUMAN RHEUMATOID ARTHRITIS - ANIMAL MODELS 
Human rheumatoid arthritis (RA) is a frequently occurring inflammatory joint 
disease, characterised by periods of acute exacerbations and remissions. 
Histopathologic studies of rheumatoid synovium show hyperplasia of the 
synovial lining and chronic inflammatory cell infiltrates that predominantly 
include macrophages, T-, and B-lymphocytes. There is a consensus that the 
monokines interleukin-1 (IL-1), tumor necrosis factor a (TNFa), IL-6, and 
granulocyte-macrophage colony-stimulating factor (GM-CSF) are present 
within the joint at high concentrations. This in contrast to the amount of T-cell 
derived cytokines, like IL-2, IL-4, and gamma-interferon (ΙΡΝγ), which is 
rather low. In the initial phase of RA T-lymphocytes might recruit and 
influence other cells through the production of lymphokines. Evidence for a 
dominant role of T-cells in an established, chronic synovitis is not defenitive.1"8 
A way to investigate the various processes involved in RA is the use of animal 
models. Animal models offer the opportunity to interfere and modulate 
inflammatory processes resembling human RA. The regulatory role of T-
lymphocytes in these processes remains unclear untili now. Several T-cell 
dependent animal models have been developed, and will be discussed briefly. 
Adjuvant arthritis (AA) can be induced in genetically susceptible strains of 
rats (e.g. Lewis) by a single injection of Mycobacterium tuberculosis in 
Complete Freund's Adjuvant (CFA), resulting in hyperplasia of the synovium, 
bone and articular cartilage erosion, and infiltration of predominantly 
lymphocytes and plasmacells and a smaller number of polymorphonuclear cells 
(PMN) into the joints.910 AA can be transferred with Τ cells from diseased 
rats or antigen specific Τ cell clones to naive recipients, and these Τ cells 
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recognise mycobacterium components as well as self antigens, like cartilage 
proteoglycans.11"14 
Streptococcal cell wall-induced arthritis can be induced in a susceptible rat 
strain (Lewis) by a single interperitoneal (i.p.) injection of cell wall fragments 
of Streptococcus group A bacteria. Rats develop an acute complement 
dependent polyarthritis and systemic illness followed by a chronic T-cell 
dependent erosive polyarthritis.15"17 The chronic inflammation is characterised 
by proliferation of the connective tissue, blood vessels, and synovium, 
infiltration by lymphocytes and mononuclear phagocytes, hyperplasia of the 
synovial lining cells and destruction of the cartilage and subchondral bone.15 
Collagen type II induced arthritis (CIA) is inducible in susceptible strains of 
mice (H-24) by subcutaneous (s.c.) immunisation with collagen type II 
emulsified in CFA.18,19 Also rat and monkey models have been described.20·21 
This autoimmune disease can also be induced in naive recipients by transfer of 
anti-collagen type II antibodies or with collagen type II reactive T-cells. The 
cellular and humoral collagen type II response seem to act in synergy.22"25 This 
polyarthritis is histologically characterised by synovial hyperplasia, infiltrates 
of PMN and mononuclear cells, exudation of cells in the joint space, marginal 
erosion, periostitis and destruction of the cartilage surface.20 
Proteoglycan-induced arthritis can be induced in female Balb/c-mice by 
intraperitoneal immunisation with chondroitinase ABC-digested fetal human 
cartilage proteoglycan emulsified in CFA. This polyarthritis is characterised by 
redness and swelling of the joints, infiltration of mononuclear cells, synovitis, 
villous pannus, and erosion of bone and articular cartilage. The development 
of arthritis is accompanied by the expression of cell-mediated and humoral 
immunity to the immunising antigen.26,27 It is possible to transfer the disease 
by injection of arthritic lymphocytes in irradiated naive mice.28 
Apart from cross-reacting autoantigens, also foreign antigens may direct the T-
cell driven arthritis. In this thesis the model of an antigen-induced arthritis 
(AIA) in mice was used, and will therefore be discussed in more detail. AIA 
can be induced by local injection of the antigen into the knee joint of mice, 
previously immunised with an antigen emulsified in CFA.2''·30 The 
development of AIA is both dependent on T-lymphocytes and the formation of 
antigen-antibody complexes.31"33 Important factors for antigen handling within 
the joint are the charge and size of the antigen. Cationic antigens (with a 
MW< 150 kDa) retain in the joint due to electrostatic interactions with the 
negatively charged cartilage structures.34"36 Shortly after intra-articular (i.a.) 
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injection of the antigen, an acute type of inflammation develops, characterised 
by influx of predominantly PMN in the synovial layers and the joint space. 
Later on, the arthritis changes into a chronic inflammation with predominantly 
mononuclear cells. A few weeks after arthritis induction, the arthritis has 
almost recovered. In this chronic phase of a smouldering inflammation, a 
small number of predominantly mononuclear cells are left in the synovium. 
During this phase of local hyperreactivity, a flare-up reaction can be induced. 
This can be achieved by systemic administration of the antigen, either orally 
or intravenously, or local injection of a small amount of antigen.35"40 This 
acute, shortlived type of inflammation is mainly characterised by large 
numbers of polymorphonuclear cells in the synovial tissue and in the exudate 
in the joint space. An important role of T-lymphocytes in this phenomenon 
was underscored by treatment with anti-lymphocyte serum or monoclonal anti-
Ia-antibodies.41·42 Decomplementation with cobra venom factor prior to the 
flare induction had no effect on the flare reaction. It was concluded that 
immune complexes play a minor role in flare reactions as compared to the 
initial phase of an AIA.41 
2. TOLERANCE INDUCTION - MECHANISMS 
Immunological tolerance refers to a state of unresponsiveness which is specific 
for a particular antigen. In vivo tolerance in adult mice can be induced in 
several ways. Two methods and possible mechanisms of immuneregulation 
involved will be described: 
* tolerance induction by administration of lymphocyte receptors (idiotypic 
regulation)(2.1) 
* tolerance induction by administration of soluble proteins (2.2) 
2.1 Idiotypic regulation 
Idiotypes are components of antigen-specific receptors on B- and T-
lymphocytes. These epitopes can act as immunogens, and other cells can 
respond to these receptors (anti-idiotypic). This regulatory mechanism exists in 
the physiological situation, but the importance for controlling immune 
responses remains doubtful. 
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Above mentioned principle was used in the development of a new model of 
tolerance induction, named T-cell vaccination. In different autoimmune 
diseases resistance can be induced by vaccinating with non-viable or low dose 
viable autoimmune T-lymphocytes. Antigen-specific lines or clones are 
rendered non-viable, after mitogen activation, by irradiation, hydrostatic 
pressure or chemical cross-linkers like glutardialdehyde. These cells are 
administered intravenously, intraperitoneally, or subcutaneously before 
immunisation, and this treatment results in reduced disease.43"48 The 
mechanism responsible for this phenomenon might be the development of an 
antigen-specific anti-idiotypic network, suppressing autoimmune T-cells. Also 
non-specific cells seem to contribute on the condition that cells are activated. 
This indicates that also the generation of an anti-ergotypic network (ergon = 
work, action) may play a role. It was claimed that a prerequisite for successful 
vaccination was a pre-existing network o f T-cells, otherwise anti-idiotypic 
responses would not develop.49"53 
2.2 Soluble proteins 
Experimentally induced tolerance in adults can be induced by administration of 
soluble protein antigens in different ways such as oral feeding54"58, 
intraperitoneal59,60, or intravenous injection.61'64 Moreover, the reached amount 
of tolerance may depend on the nature of the antigen involved. This was 
demonstrated in experimental models by modifying proteins, like cationisation 
or polymerisation.6568 Modulation before immunisation is relatively easy, 
whereas only a few reports demonstrate suppression in an established 
immunity or disease.60-69 The susceptibility to tolerisation of T- and B-cells 
differs. T-cell tolerance can be achieved with rather low doses of antigen and 
within a few hours. Tolerance of B-cells requires much longer time and higher 
doses.70·71 
Several possible mechanisms for the phenomenon of Τ cell tolerance have 
been described. Three mechanisms including (1) the generation of antigen-
specific CD8+ T-lymphocytes, (2) a shift in Thelper J Th d p e r 2 balance, and (3) 
the induction of anergy of antigen-specific T-lymphocytes, will be successively 
discussed. 
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2.2.1 Antigen-specific CD8+ T-lymphocytes 
Some time ago, the existence of suppressor epitopes on proteins and the 
balance between suppressor and immunodominant epitopes was a generally 
accepted vision. These suppressor epitopes, once generated, are able to create 
and/or activate T,up])reM„ (Ts) cells, whereas stimulatory epitopes predominantly 
generate Thdper (Th) cells.72"74 These epitopes are not the same for all mouse 
strains; different T-cell responses were measured on a set of synthesised 
peptides by different Major Histocompatibility Complex haplotypes.75"77,78 
Relatively small synthetic peptides were tested. No analysis has been reported 
describing which sequences could be released during the initial steps of 
processing and proteolysis. These steps reside within the endosomal/lysosomal 
compartment of the antigen presenting cell (APC), where proteases like 
cathepsin D, and to a lesser extent cathepsin B, seem to play a dominant 
role.79"82 
Suppressor determinants, administered directly in a soluble form, might 
predominantly generate Ts cells, and could therefore be a potent way to induce 
tolerance. This vision, and the existence of CD8+ Ts cells became less 
popular, because Ts cells could not be isolated. Lately the belief in these cells 
has gained popularity again, and research is focussed on Ts cells again.8385 
The activity of Ts cells is claimed to be antigen specific as responses to 
irrelevant antigens are not suppressed. The cells exert their suppressive action 
either through the production of soluble suppressor factors like transforming 
growth factor-ß (TGFß), or through direct cell-cell contact involving antigen-
specific recognition or anti-idiotypic recognition.86"88 However, non-specific 
suppressor mechanisms by stimulation of the production of soluble suppressive 
factors have also been demonstrated. This way of suppression is termed 
'antigen-driven bystander suppression'.89,90 By administration of an irrelevant 
soluble antigen, T-cells are generated which release antigen non-specific 
factors like TGF/3. These locally produced factors are capable of mediating 
suppression of the relevant disease or immunity. The secretion and action of 
these soluble factors has to occur in the local environment of the lymphoid 
tissue where the immune response is generated and/or at the inflamed site in 
the target organ. 
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2.2.3 Anergy of antigen-specific T-lymphocytes 
Anergy is a state of functional inactivation, which can be induced by 
occupation of the T-cell receptor (TCR) in the absence of a co-stimulatory 
signal. Non-professional APC lack the ligand B7, and therefore no interaction 
can take place with the CD28 receptor on T-lymphocytes. Ligation of CD28 
induces increased transcription and stabilisation of lymphokine mRNA in 
responding T-cells.83103'04 Anergic Τ cells are characterised by a reduced 
capacity to proliferate, and IL-2 production, and a diminished IL-2 receptor 
expression in response to specific antigenic stimulation. This state of 
unresponsiveness has been demonstrated not to be a permanent change in the 
T-cell, but can be reversed in vitro as well as in vivo by rIL-2 
stimulation.99105"107 The reversal of anergy can be used as a tool to study 
processes involved in tolerance induction. 
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Figure 1. Diagram of the prominent regulatory interactions between CD4+ T-
cell subsets. 
3. AIM OF THIS STUDY 
In this thesis several approaches to modulate T-cell immunity are investigated. 
Detailed analysis is done to understand underlying mechanisms. 
In chapter 2 the feasibility of T-cell vaccination is tested beyond the area of 
autoimmunity, in a model system of immunity directed to foreign protein 
antigens. Even by using antigen-specific bulk lymph node cells instead of T-
cell lines or clones, antigen-specific suppression could be reached. The degree 
of suppression seemed to be dependent on the type of antigen used. This was 
also demonstrated in orally and intravenously induced tolerance (chapter 3). 
Administration of native proteins induced clear suppression, in contrast to their 
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cationic derivatives. This implicates that successful immunointervention may 
be highly dependent on the nature of the antigen involved. Differences in 
degree of tolerance induction might be explained by a disturbed balance 
between suppressive and stimulatory T-cell epitopes. To obtain insight in the 
in vivo released epitopes after antigen processing, in order to modulate an 
established immunity with these kind of epitopes, model studies were carried 
out. Chapter 4 describes the release of stimulatory T-cell peptides of hen egg 
lysozyme by the endosomal/lysosomal proteases cathepsin В and D. The 
relative long fragments were predominantly released by cathepsin D. T-cell 
responses of three strains of mice (different class II MHC haplotypes) on these 
peptides showed marked similarities, in contrast to studies done with 
synthetically, relatively short prepared peptides. 
Latest developments in the field of immunology gave rise to new visions about 
mechanisms of T-cell tolerance. In chapter 5 and 6 possible underlying 
mechanisms of intravenously induced tolerance with hen egg lysozyme (as 
demonstrated before in chapter 3) are studied. Tolerance was antigen-specific, 
and no antigen-driven bystander suppression could be generated in our model. 
No role for CD8+ T-lymphocytes could be demonstrated, and also a shift in 
Thl/Th2 balance (resulting in a change in IL-4 and IL-10 production) seemed 
not to be the mechanism of tolerance. Reduced T-cell proliferation and IL-2 
production in vitro was demonstrated, which could be reversed by rIL-2 
stimulation. This leads to the conclusion that anergy of antigen-specific T-
lymphocytes is the mechanism of tolerance in intravenously induced 
suppression with hen egg lysozyme. 
In chapter 7 the role of Thl and Th2 cells is studied in a model for acute 
exacerbations, only inducible in hyperreactive joints. Monoclonal antibody 
treatments directed to IL-2 as well as to IL-4 were able to abrogate the flare-
up reactions, indicating a pro-inflammatory role for the generally entitled anti­
inflammatory Th2 cell. Considering the Th2-cell derived cytokine IL-4 for 
therapeutic purposes, one should be aware of the pro-inflammatory potentials. 
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CHAPTER 2 
INDUCTION OF TOLERANCE BY T-CELL VACCINATION IS 
POSSIBLE BEYOND THE AREA OF AUTOIMMUNITY: DOWN-
REGULATION OF IMMUNITY DIRECTED TO FOREIGN PROTEIN 
ANTIGENS 
Marike J.M. Jacobs, Astrid E.M. van den Hoek, Levinus B.A. van de Putte 
& Wim В. van den Berg. 
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SUMMARY 
T-cell vaccination using antigen-specific lines or clones has been shown to be 
effective in down-regulating immunity in various experimental autoimmune 
models. Anti-idiotypic networks developing during differentiation of the 
immune system are considered to be a safeguard against autoimmunity and 
these pre-existing networks are supposed to be a prerequisite for successful 
vaccination. However the interesting question of feasibility of T-cell 
vaccination beyond the area of autoimmunity remains to be answered. The 
present study is the first one providing evidence of successful T-cell 
vaccination in mice immunised against foreign protein antigens (in this system 
supposedly no pre-existing network exists). Intraperitoneal (i.p.) administration 
of hen egg lysozyme (HEL)- and chicken egg albumin (OVA)-specific lymph 
node cells (LNC) were shown to effectively down-regulate immunity (as 
measuered in a delayed type of hypersensitivity) to HEL and OVA, 
respectively. In contrast, vaccination was unsuccessful with methylated bovine 
serum albumin (mBSA)-specific LNC in mBSA-immunity. Suppression 
induced by HEL- and OVA-specific LNC was antigen specific. Unlike the 
greater part of other studies, in which antigen-specific lines or clones were 
used, we used draining LNC of immunised mice, that after activation were 
22 Chapter 2 
fixed with glutardialdehyde and injected i.p. ten days before immunisation. 
Finally, effects of T-cell vaccination were studied in a chronic HEL-induced 
arthritis. Joint swelling, cell influx and cartilage matrix depletion were 
significantly less in mice treated with antigen-specific cells. We conclude that 
successful vaccination is feasible in mice rendered immune to foreign protein 
antigens using a pool of LNC as source of vaccine, suggesting no necessity of 
a strong pre-existing network. 
INTRODUCTION 
Down-regulation of immunity has been extensively studied in several 
experimental autoimmune models [EAE, adjuvant arthritis (AA), experimental 
allergic thyroiditis (EAT), and collagen induced arthritis (CIA)]. Different 
ways of inducing T-cell suppression are described, like i.v. and oral 
administration of specific antigen or epitopes.1"9 A few years ago, another 
approach of tolerance induction was developed. Resistance to autoimmune 
disease was induced by vaccinating with nonviable or low-dose viable 
autoimmune T-lymphocytes.10"15 T-lymphocytes were rendered nonviable (after 
mitogen activation) by irradiation, hydrostatic pressure or chemical cross-
linkers. Cells were administered i.v., i.p. or s.c. into the back or footpads. 
All procedures of vaccination were effective in inducing tolerance.111617 
By vaccination, cells recognising specific receptors on the autoimmune T-cell 
develop. This anti-idiotypic network is held responsible for suppressing 
autoimmune T-cells and disease does not develop.1211·1618"-1 Other reports show 
effects of non-specific T-cells on the condition that cells are activated. This 
indicates that an anti-ergotypic (ergon = work, action) response is also 
important.22 According to the greater part of literature, a prerequisite for 
successful T-cell vaccination is a pre-existing network of T-cells, otherwise 
anti-idiotypic responses will not develop.13,20·23 This is by common consent the 
case in experimental autoimmune diseases. So far, only one study is known in 
which effects of T-cell vaccination beyond the area of autoimmunity are 
shown. In this study, using a model of contact sensitivity, immunogenicity of 
T-cells was achieved through combination with carrier molecules which are 
self-antigens themselves.23 
To investigate if T-cell vaccination was possible in a model in which a strong 
pre-existing network supposedly does not exist, experiments were carried out 
in animals rendered immune to foreign protein antigens. Total immune lymph 
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node cell (LNC) populations were taken as sources of cells to vaccinate i.p. 
ten days before immunisation. After activation by mitogen, these cells were 
fixed by glutardialdehyde or administered viable in low doses. This way of 
intervention is less antigen-specific than vaccinating with clones in a passively 
transferred disease. In order to achieve a more antigen-specific treatment, 
vaccination was carried out with antigen-specific clones and hybridomas. 
Earlier work shows that the capacity to induce oral or i.v. tolerance is not 
equal for all types of antigens.24 This could also be the case in intervention by 
T-cell vaccination. Therefore different antigen-specific LNC, such as 
methylated bovine serum albumin (mBSA), OVA, and hen egg lysozyme 
(HEL), were studied regarding their potency to induce suppression. Immunity 
was measured by ear challenge tests (DTH), illustrating short term 
inflammatory processes. Even more relevant are effects of T-cell vaccination 
on more chronic processes. We therefore studied inflammatory infiltrate, 
exudate and cartilage destruction in a model of chronic joint disease. In this 
way insight was gained into the feasibility of T-cell vaccination beyond the 
area of autoimmunity. 
MATERIALS AND METHODS 
Materials 
Female C57B1/6 mice, aged 12-15 weeks, were bred in the Central Animal 
Laboratory. Bovine serum albumin (fraction V), methylated BSA (grade V), 
chicken egg albumin (grade III), hen egg lysozyme (grade I), l-ethyl-3(3-
dimethyl-aminopropyl) carbodiiminehydroxychloride(EDC), and poly-L-lysine 
(PLL)(56 kD) were obtained from Sigma (St. Louis, MO, USA). To raise 
MW, HEL was coupled to PLL using EDC as activator. Coupled PLL was 
separated from free HEL by Sephadex G75 gel filtration. The ratio HEL/PLL 
in the coupled product was found to be l.25 OVA was amidated by coupling 
amino groups to free carboxyl groups of the protein, using EDC as activator 
and DMPA as a nucleophile, according to the method of Danon et al. ,26 
Immunisation 
Mice were immunised in the footpads of the forelegs and subcutaneously in 
the flanks with 200 μg antigen emulsified in Complete Freund's Adjuvant 
(Difco, Detroit, MI, USA). Additionally, 2x10" heat-killed Bordetella pertussis 
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organisms (National Institute of Public Health, Bilthoven, the Netherlands) 
were administered i.p.. In groups of animals used for induction of antigen 
induced arthritis (AIA), booster injections were given s.c. seven days later. 
Preparation of vaccine 
To obtain Ag-specific LNC, mice were immunised, and 7 days later boosted 
in the footpads of the forelegs with 50 μg Ag/CFA. Three days after 
boostering draining lymph nodes (LN) were isolated and single cell 
suspensions were made. Cells were washed once in RPMI-1640 Dutch 
modification (dm)(Flow laboratories, Zoetermeer, the Netherlands). Cells were 
activated (2x10* cells/ml) by incubation with the T-cell mitogen concanavelin 
A (con A)(Flow laboratories) for 72 h at a concentration of 2.5 μg/ml. After 
activation cells were washed 3 times, and adjusted to 1x10" cells per 50 ml 
0.3% glutardialdehyde (Merck, Darmstadt, Germany) solution in phosphate 
buffered saline (PBS). After fixation for 15 min at room temperature cells 
were washed four times in PBS. Fixed cells were adjusted in PBS to the right 
concentration and 1 ml was injected i.p. into naive mice 10 days before 
immunisation. In case of vaccination with viable cells, cells were injected i.p. 
immediately after con Α-activation and washing three times. 
Clones and hybridomas 
mBSA- and OVA-specific T-helper clones of C57B1/6J origin were generated 
as described elsewhere.27 To maintain Ag-specificity, the clones were 
restimulated for three days every 5-6 weeks with 5 μg mBSA/ml or 300 μg 
О V A/ml. 
mBSA-specific T-cell hybridomas were generated by fusion of BW5147 
tumour cells and AKR-derived lymphocytes (H-2k) as described elsewhere.28 
Clones and hybridomas were used for vaccination when Ag-specificity, tested 
in proliferation assays, was high. 
Skin testing 
Ten days after immunisation, delayed type of hypersensitivity (DTH) was 
tested by injecting 10 μg mBSA or amidated OVA into the left ear (5 μΐ). 
Amidation of proteins augments retention of the Ag. HEL-immunity was 
tested by injecting 50 ^g of HEL. Ear thickness was measured after 48 h with 
an industrial micrometer. Values are expressed as left/right (L/R) ratios. 
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Arthritis induction and determination 
Mice were injected intraarticularly (i.a.) in the right knee joint with 25 μg 
PLL.HEL in 6 μ\ PBS, 14 days after boosting. Joint inflammation was 
determined 3 and 7 days after arthritis induction by measurement of " T c 
pertechnetate uptake of the knee joint. Mice were sedated with chloral hydrate 
(i.p.) and injected sc in the neck region with 10 /¿Ci T c . After 20 min, 
radioactivity was assessed by measuring both knees in a fixed position. Joint 
swelling was expressed as the ratio of the WmTc-uptake in the right and left 
knee joints (R/L ratio).25 
Histology 
On days 3 and 7 after arthritis induction groups of at least 6 mice were killed. 
Knee joints were dissected and processed for histology, as described 
previously.30 Whole knee joint sections (6 μπι) were prepared and stained with 
heamatoxylin/eosin and saffranin O, respectively. Arthritis was scored 
semiquantitatively in a standardised frontal section of the knee joint which 
included menisci, cruciate ligaments and the patella. Extent of cellular 
infiltration of synovial tissue, cellular exudate in the joint space, and cartilage 
destruction were graded on a scale ranging from 0 (no cells or matrix 
depletion) to 3. 
Proliferation assay 
T-cells were examined for Ag-specificity and response to vaccinated cells by a 
3[H]thymidine incorporation assay. Fourteen days after immunisation or seven 
days after arthritis induction, mice were sacrificed and draining LN were 
removed aseptically. A single cell suspension was made by gentle teasing in a 
sterile infusion system (NBPI BV, Emmer-Compascuum, the Netherlands). 
Cells were washed once and enriched for T-lymphocytes by nylonwool 
adherence (30 min). Non adherent cells were collected and adjusted to a 
concentration of 2xl06/ml. As the source of antigen presenting cells (APC), 
naive spleen cells were used. Spleens were removed aseptically, a cell 
suspension was made, and erythrocytes were lysed with 0.16 M NH4C1 0.17 
M TRIS-HC1, pH 7.2 for 1 min at room temperature. Cells were washed three 
times and adjusted to a concentration of lxl07/ml. Proliferation medium 
consisted of RPMI-1640dm completed with 20 mM glutamine, 10 mM 
pyruvate, 0.5 mM /3-mercaptoethanol and 2% homologous serum. In 96-well 
round-bottom microtitre plates (Costar, Cambridge, MA) different Ag-, con 
A-, and glutardialdehyde fixed cell concentrations (1x107ml up to 5xl0*/ml) 
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Statistics 
Results are expressed as mean ± standard deviation. Statistical significance 
was tested by using the Wilcoxon's Rank Sum test. Significance was reached 
when Ρ values were less then 0.05. 
RESULTS 
T-cell vaccination with total LNC-populations 
Mice were immunised and boosted with mBSA emulsified in CFA in the 
footpads of the forepaws. Three days after boosting, draining lymph nodes 
were removed. Cells were con A activated in vitro and fixed by 
glutardialdehyde. 
L/R ratio 
1 00 
Figure 1. A dose range of 
glutardialdehyde-fixed 
mBSA-specific LNC was 
tested in their ability to 
suppress mBSA-immunity 
(hatched bars). Cells were 
administered i.p. 10 days 
before immunisation. Control groups received PBS (black bars). On day 10, 
immunity was tested by ear challenge tests (DTH at 48 hr). Values are 
expressed as the mean (± sd) of L/R-ratios of 7 mice per group. * p< 0.05. 
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Different cell concentrations were injected i.p. 10 days before immunisation, 
in order to induce immunosuppression. Control groups received PBS. Results 
in figure 1 show no significant suppression of DTH, although a slight trend to 
suppression was observed. 
It is clear from earlier work that not all types of protein antigens possess equal 
capacity to induce tolerance. Oral and i.v. administration of cationic mBSA 
induce suppression of DTH and arthritis after extremely high dosages, in 
contrast to OVA and HEL.24 Therefore other antigen-specific T-cells were 
tested for capacity of T-cell vaccination. Figure 2 shows results of two 
representative experiments performed with fixed HEL- and OVA-specific LNC 
(after con Α-activation) in HEL-immune and OVA-immune mice, respectively. 
In a first experiment 5xl07 HEL-specific LNC were injected i.p. 10 days 
before immunisation. Results show a significant suppression of DTH in the 
treated group compared to the PBS control group (figure 2a). Similar results 
were obtained by vaccination with OVA-specific LNC in OVA-immune mice. 
DTH in treated groups was suppressed and suppression seemed to be dose-
dependent (figure 2b). 
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Figure 2. Glutardialdehyde-flxed HEL-specific LNC (5xI07)(a) or OVA-
specific LNC (2.5x107 and 5xl07)(b) were administered i.p. 10 days before 
HEL- or OVA-immunisation, respectively. Control mice received PBS (black 
bars). Ten days after immunisation, immunity was tested by ear challenge tests 
(DTH at 48 hr). Values are expressed as the mean (± sd) of L/R-ratios of 7 
mice per group. * p< 0.05. 
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In addition, proliferative responses of non-adherent lymph node cells were 
performed and data obtained show an antigen-specific suppression (figure 3), 
while con Α-responses remained identical for all groups. No proliferative 
response on cells used as vaccine could be found. Anti-OVA titres, measured 
by ELISA, were equal for all groups (data not shown). 
OVA 100 OVA 50 
\ig antigen/ml 
Figure 3. In vitro proliferative responses of non-adherent LNC of PBS 
(control) and OVA-vaccinated groups (figure 2) to different OVA 
concentrations. Con A responses were equal for all groups (data not shown). 
Values are expressed as delta counts per minute (background cpm amounted to 
about 650 for all groups). 
In order to investigate if suppression was antigen-specific and not partly anti-
ergotypic (as described in ref. 22), criss-cross experiments were performed. 
HEL-immunised animals were treated before immunisation with 5xl07 
glutardialdehyde fixed HEL-specific LNC, fixed OVA-specific LNC or PBS, 
respectively. Three days after arthritis induction, joint swelling was measured. 
Results in table 1 show no effect on joint swelling by administration of OVA-
specific cells. 
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Table 1. Effects of HEL-specific T-cell vaccination on joint swelling. 
Treatment 
PBS 
OVA-LNC 
HEL-LNC 
Joint swelling 
1.71 ± 0.21 
1.75 ± 0.30 
1.37 ± 0.15' 
Glutardialdehyde fixed HEL-specific LNC (5xl07) were administered i.p. 10 
days before HEL-immunisation. Control mice received resp. PBS or fixed 
OVA-specific LNC. Three days after induction of arthritis, joint swelling was 
measured. Values are expressed as the mean (± sd) of R/L-ratios of 8 mice 
per group. *p< 0.05. 
Additionally, OVA-immunised animals were treated with glutardialdehyde 
fixed HEL-specific LNC. No suppression of OVA-specific DTH could be 
induced by vaccinating with HEL-specific cells: immunity was equal compared 
with the PBS-treated group (data not shown). 
Further attempts were focused on optimalisation of T-cell vaccination using 
enriched populations of OVA-specific T-cells. Therefore different ways of in 
vitro stimulation were used. These consisted of con A-, con A and OVA (300 
μg/ml), or IL-2 (12.5% spleen supernatant) and OVA (300 Mg/ml) stimulation 
for 3 days in vitro. Three groups of mice were treated i.p. with 5xl07 
glutardialdehyde-fixed cells 10 days before immunisation. Control mice 
received PBS. All treated groups showed a significant suppression of DTH 
(about 45%) in comparison with control group. No significant differences 
were seen between the treated groups. Therefore con A-stimulation was 
maintained as a way to stimulate LNC in vitro. 
T-cell vaccination with mBSA-specific hybridomas and clone 
A disadvantage of vaccinating with pools of LNC is the small percentage of 
antigen-specific cells, and this may be an alternative explanation for the lack 
of effect of T-cell vaccination as found in mBSA-immune mice. Therefore a 
mBSA-specific T-cell clone and three mBSA-specific T-cell hybridomas were 
used as sources for vaccination. A dose-range of 5x10* to 5xl07 
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glutardialdehyde-treated cells were injected i.p.. Ten days later mice were 
immunised with mBSA/CFA. We were unable to induce significant 
suppression of DTH in mBSA-immunised mice (data not shown). 
Effects of T-cell vaccination on Antigen-Induced-Arthritis 
To investigate the impact of T-cell vaccination on a more chronic process, the 
T-cell dependent model of AIA was used. Immunomodulation in this model 
might be harder, because mice receive an extra booster injection in order to 
deyelop a chronic arthritis. Arthritis was induced two weeks after boosting by 
injecting 25 ^g PLL.HEL into the right knee joint. Ten days before 
immunisation, mice were treated i.p. with 5xl07 con A-stimulated, 
glutardialdehyde-fixed HEL-specific LNC. Control mice received 5xl07 fixed 
BSA-specific LNC or PBS. Figure 4 shows articular swelling on days 3 and 7 
after arthritis induction. The group treated with glutardialdehyde HEL-specific 
cells showed a significant reduction in articular swelling on day 3 as well as 
day 7. 
R/L-ratio 
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Figure 4. Effect of SxlO7 glutardialdehyde-fixed HEL-specific LNC on 
articular swelling in HEL-induced arthritis (open bars). Control mice received 
PBS (black bars) or 5x107 fixed BSA-specific LNC (hatched bars). Values 
measured 3 and 7 after arthritis induction are expressed as the mean (± sd) of 
R/L-ratios of 8 mice per group. * p< 0.05. 
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Seven days after arthritis induction, mice were sacrificed for histology and 
execution of proliferation assays. Histological findings in table 2 confirm the 
results (figure 4) of reduced joint swelling. Treatment with fixed BSA-specific 
LNC (control) showed no effect on HEL-induced arthritis. Cell influx in 
synovial tissue and joint space, and also matrix depletion of cartilage where 
the same as in the PBS control group. However, treatment with 
glutardialdehyde HEL-specific LNC induced significant reduction of cell 
infiltrate, while the exudate was significantly less than in the BSA-LNC treated 
group. Loss of proteoglycans in the cartilage was considerable in the HEL-
treated group, but still significantly less than control groups. These data 
illustrate effectiveness of T-cell vaccination on chronic processes like a HEL-
induced arthritis. 
Table 2. Effects of HEL-specific T-cell vaccination on histology. 
Treatment Infiltrate Exudate Matrix depletion 
PBS 2.0 ± 0.8 0.4 ± 0.2 3.0 ± 0.0 
BSA-LNC 2.4 ±0.7 0.8 ± 0.3 3.0 ± 0.1 
HEL-LNC 0.9 ± 0.3" 0.2 ± 0.2* 2.0 ± 0.5" 
Effects on histological findings in a HEL-induced arthritis on day 7 (articular 
swelling is shown in figure 4). Mice (n = 8lgroup) were treated with 5x107 
fixed HEL-specific LNC ten days before immunisation. Control mice received 
5xl07 fixed BSA-specific LNC or PBS. Severity of parameters ranges from 0 
(normal) to 3 (severe). * p< 0.05 compared with BSA-LNC; ** p< 0.05 
compared with PBS and BSA-LNC. 
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DISCUSSION 
The efficacy of T-cell vaccination, using Ag-specific lines or clones, in 
inducing tolerance has been well demonstrated in many experimental 
autoimmune models.111517,29·30 Before administration, cells are attenuated by 
irradiation, pressure or fixation. All these procedures of attenuating cells are 
more or less effective in preventing EAE.17·22 Later on, it was discovered that 
administering a subencephalitogenic dose of viable autoimmune effector cells 
prevented rats from developing EAE.1618 Different routes of administration, 
like i.v., i.p., and s.c. in back or footpads, were all effective in the induction 
of tolerance.16 In other autoimmune diseases like EAT, CIA, and AA, T-cell 
vaccination was effective in preventing actively or passively transferred 
disease.111215'3133 Prerequisite for successful vaccination seems to be the 
presence of pre-existing anti-idiotypic networks, developed during 
differentiation of the immune system as a safeguard against autoimmune 
diseases. We are aware of only one study in which effects of vaccination 
beyond the area of autoimmunity were shown, viz. in experimental contact 
sensitivity.23 It should be noted that immunogenicity to chemicals, which are 
haptens, is acquired through combination with carrier molecules, which are 
self-antigens themselves. 
The present study indicates that T-cell vaccination can be effective in 
immunity induced by foreign protein antigens. However not all kinds of 
protein antigens possess equal capacities to induce oral or i.v. tolerance.24 This 
was also found with T-cell vaccination, which was not effective in mBSA 
immune mice (figure 1), while vaccination in OVA- and HEL-immune mice 
induced significant tolerance in DTH (fig. 2). T-lymphocytes used for 
vaccination were obtained by immunising mice in the footpads of the forepaws 
and isolating draining LN. This pool of LNC contained not only Ag-specific 
but many non-specific cells. Isolated LNC were then activated in vitro by con 
A, a prerequisite for effective vaccination. Activation induces changes and 
better expression of membrane components on T-lymphocytes, probably 
necessary for successful vaccination.34 Moreover, activated (mostly Ag-
specific) T-lymphocytes are better stimulated by con A than inactive (mostly 
non-specific) lymphocytes. This results in a higher percentage of Ag-specific 
cells after activation.14 Different conditions of in vitro activation of a pool of 
LNC were tested. Results showed that an expected 'better' Ag-specific 
stimulation, using con A + Ag or IL-2 + Ag, was not more effective than 
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con A-stimulation alone; equal suppression was achieved in all groups. 
Immunising with total protein Ag induces immunity to many epitopes. In 
experimental autoimmune models described earlier"·15,17·29·30, disease was 
suppressed by vaccination with epitope-specific clones or lines. The lack of 
effect of T-cell vaccination with mBSA-specific LNC might be explained by 
the use of a small percentage of antigen-specific cells. We therefore tried to 
give more Ag-specific cells by testing a mBSA-specific clone, and three 
mBSA-hybridomas. No suppression could be induced, even not by 
administering high doses of cells. Also in OVA-immunity, in which successful 
vaccination was demonstrated by pools of LNC, no suppression could be 
induced by vaccination with an OVA-specific clone (data not shown). 
However definite conclusions cannot be drawn, before a set of clones with 
known epitope specificity is tested. 
As mentioned earlier, effective T-cell vaccination in autoimmune diseases 
could be achieved by administration of low dose of viable cells, or by 
vaccinating with attenuated cells (by irradiation, fixation or pressure 
treatment). Our results show suppression only by administration of cells fixed 
with glutardialdehyde; administration of low dose viable cells could not induce 
any suppression (data not shown). Experiments to study other procedures of 
attenuating cells are in progress. 
The impact of T-cell vaccination on more chronic T-cell dependent processes 
(like the chronic inflammation of AIA) may be clinically even more relevant. 
Immunomodulation in this model might be harder, because the immunisation 
protocol used includes not only a single immunisation procedure, but also a 
booster injection. Results (figures 4,5 and table 2) demonstrated that treatment 
with glutardialdehyde-fixed T-lymphocytes before immunisation significantly 
suppressed articular swelling and histological parameters, like cell infiltrate 
and exudate and cartilage destruction. In all experiments performed, vaccine 
was administered ten days before immunisation. Further investigations are now 
in progress and aimed at interference with AIA just before arthritis induction 
and before a flare-up, that may be more relevant for the human situation.35 
From the present data one could only speculate on the mechanism of 
suppression after vaccination. Proliferation assays performed with spleen cells 
and LNC from suppressed mice showed reduced response to the antigen 
involved, however no response could be measured to cells used as vaccine. 
Previous studies have mentioned the development of an anti-idiotypic network 
as an explanation of successful T-cell vaccination.12·131618'21 Possibly a pre-
existing network, present in autoimmune diseases, is necessary to create a 
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detectable anti-idiotypic network. More experiments at different time-points 
after vaccination should allow for obtaining further insight into the 
mechanism. The contribution of anti-ergotypic networks (not Ag-specific, just 
activated T-lymphocytes) is also described as a possible explanation of 
tolerance induction.22 However it is unlikely that the latter type of network 
plays a part in our model, because in control studies, activated non-specific T-
lymphocytes could not suppress immunity (table 1). The mechanism of 
suppression does not necessarily have to act via direct cell-cell contact, since 
regulation via cytokines, like Interleukin-4 (IL-4), IL-10 or transforming 
growth factor /3, may also be of importance.36 So far the underlying 
mechanism of T-cell vaccination remains unknown. 
We conclude that T-cell vaccination before immunisation by using a pool of 
LNC as source of vaccine is an effective way of suppressing or preventing 
immunity, also in a model of chronic joint inflammation. Our data suggest that 
the presence of pre-existing networks is not necessary for this effect. At this 
moment the usefulness of the procedure in human rheumatoid arthritis is 
uncertain, because the disease is already ongoing and in addition, the putative 
antigen is unknown. 
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CHAPTER 3 
ABERRANT TOLERANCE INDUCTION WITH CATIONIC ANTIGENS 
Marike J.M. Jacobs, Astrid E.M. van den Hoek, Levinus B.A. van de Putte 
& Wim В. van den Berg. 
Scandinavian Journal of Immunology 37: 97-103; 1993. 
ABSTRACT 
We studied the induction of tolerance in female C57Bl/6-mice by oral and 
intravenous (i.v.) administration of protein antigens before immunisation. 
Native proteins [chicken egg albumin (OVA), bovine serum albumin (BSA)] 
and their cationic derivatives [amidated (a)OVA, aBSA, methylated (m)BSA] 
were compared in their capacity to suppress cell mediated immunity (CMI), as 
measured by a delayed type of hypersensitivity test (DTH). Oral feeding of 
0.5 mg native proteins gave a clear suppression. By contrast, cationic 
derivatives (50 μ% to 50 mg) did not suppress CMI. Data from cross-
experiments, where aOVA was fed in OVA-immune mice, showed no 
suppression at all. When OVA was fed in aOVA-immune mice, only a partial 
suppression was achieved. 
The potency to induce tolerance differed also when the antigens were 
administered i.v.: 25 μg OVA was sufficient to induce a clear suppression, 
whereas a much higher amount of aOVA (500 μg) caused marginal 
suppression in OVA- and aOVA-immune mice, respectively. Nevertheless, 
when concentrations of aOVA up to 2.5 mg were tested in a chronic model of 
arthritis, significant suppression was achieved. 
The differences in inducing a CMI suppression may have implications for the 
feasibility of immunointervention. Successful modulation of human arthritis 
may be highly dependent on the nature of the antigen involved. 
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INTRODUCTION 
Oral administration of protein antigens to naive animals can induce a state of 
tolerance.1"5 This can be a suppression on T-cell, as well as on B-cell level. A 
plausible mechanism for the induction of tolerance is the involvement of T-
suppressor cells.2·6"10 Other possibilities, probably less plausible, are that T-
helper cells may come in a state of anergy or that clonal deletion takes 
place.9,10 Induction of tolerance has been described for many antigens, both for 
foreign and autoantigens.4,911"14 Other studies show that suppression on B-
and/or T-cell level may be highly dose-dependent. Suppression on T-cell level 
is often easily achieved, whereas suppression on B-cell level is only inducible 
after very high doses of antigen.1516 Oral feeding is not the only possibility to 
affect tolerance. Other ways of administering an antigen, e.g. intravenous 
(i.v.) administration, can be very effective. Suppression by this way of 
intervention has been described for proteins as well as peptides.141720 Current 
research is focussed on the potential application of immunomodulation to the 
treatment of chronic diseases and studies have been performed in experimental 
autoimmune models like adjuvant and collagen arthritis or allergic 
encephalomyelitis (EAE). Promising results were obtained in EAE by feeding 
major basic protein (MBP) or its fragments. However, our own attempts to 
modulate methylated bovine serum albumin (mBSA) induced arthritis, by oral 
feeding of cationic mBSA were negative. This may indicate that the chance of 
successful immunomodulation depends on the type of antigen involved and 
prompted us to perform a study comparing native and cationic proteins. We 
compared a number of native and cationised proteins for their potency to 
induce oral suppression of delayed type of hypersensitivity reactions. 
Moreover, cross-studies were performed using either the cationised or native 
form to modulate and test immunity. Finally, antigens were given i.v., and the 
impact of immunomodulation was studied on later stages of arthritis. Our data 
support the view of aberrant tolerance induction with cationic proteins, and 
underline that successful immunomodulation of chronic human diseases may 
be highly dependent on the particular type of antigen involved. 
Cationìc antigens 39 
MATERIALS AND METHODS 
Materials 
Female C57B1/6 mice aged 12-16 weeks were used. They were bred in the 
Central Animal Laboratory. Bovine serum albumin (BSA)(fraction V), chicken 
egg albumin (OVA)(grade III), mBSA (grade V), and l-ethyl-3(3-dimethyl-
aminopropyl) carbodiimine hydrochloride (EDC) were obtained from Sigma 
(St. Louis, MO, USA). N,N-dimethyll,3-propanediamine (DMPA) was 
obtained from BDH Chemicals Ltd (Poole, U.K). OVA and BSA were 
transformed to their cationic derivatives by coupling amino groups to free 
carboxyl groups of the protein, using EDC as activator and DMPA as a 
nucleophile, according to the method of Danon et al. .21 The pi of amidated 
(a)OVA and aBSA were increased to ± 10.0. This was determined in a 5% 
Polyacrylamide slab gel with 0.8% ampholines (pH gradient from 3.5 to 
9.5)(isoelectrofocussing gels),22 
Immunisation 
Mice were immunised in the footpads of the forelegs and subcutaneously in 
the flanks with 200 μg antigen emulsified in Complete Freund's Adjuvant 
(CFA)(Difco, Detroit, MI, USA). 
Induction of tolerance 
To induce oral tolerance mice were fed protein in 0.5 ml aqua dest by 
intragastric intubation, 7 days before immunisation. Control mice received an 
equal amount of casein. 
To induce i.v. tolerance mice were injected with protein in 0.2 ml PBS in the 
tail vein, 6 days before immunisation. Control mice received casein in PBS. 
Antibody-assay 
Antibodies (Ab) were determined in sera of individual mice with an enzyme 
linked immunosorbent assay (ELISA). Polystyrene microtitre plates (Costar, 
Cambridge, MA, USA) were coated overnight at room temperature with 150 
μΐ of antigen solution per well. The concentration of BSA-, aBSA-, mBSA-, 
and aOVA-solution amounted 10 μg/ml phosphate buffered saline (PBS), and 
the OVA-concentration was 100 ¿ig/ml PBS. The plates were washed three 
times with 0.05% Tween-20 in PBS, and coated with 150 μΐ 1% gelatin 
dissolved in PBS (1 h, room temperature) to avoid non-specific binding. After 
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washing, plates were incubated with two-fold dilutions of the sera (in 0.5% 
gelatin in PBS, 1 h, room temperature). The plates were washed three times 
and incubated (1 h, room temperature) with 1:500 diluted goat anti-mouse Ig-
PO (Nordic, Tilburg, The Netherlands). After washing five times, substrate 
(10 ml 50 mM NaPi, 8 mg 5-aminosalicylacic, and 8 μ\ 30% H202) was 
added, and after 20 min extinction was measured at 450 nm. Ab-titre was 
expressed as the dilution at a half maximum extinction. 
Skin testing 
Fourteen days after immunisation, Arthus reaction and delayed type of 
hypersensitivity (DTH) were tested by injecting 10 μg cationic, or 50 ^g 
native protein in the left ear (5 μΐ). Due to cross-reactivity on T-cell level, 
both antigens can be used as test antigen. The cationic protein gives the best 
retention, and is therefore generally used as test antigen.23 Ear thickness was 
measured after 4, 24, and 48 h with an industrial micrometer. Values are 
expressed as left/right (L/R) ratios. Proportional suppression was calculated as 
follows: 
(L/R(con„ol) - L/R(exp)) / (1 - L/R(con„oll) χ 100%. 
Arthritis induction and determination 
Mice were injected intra-articularly (i.a.) in the right knee joint with 60 μg 
antigen in 6 μΐ PBS, 14 days after immunisation. Joint inflammation was 
determined at day 3 and 7 after arthritis induction by measurement of W mTc 
pertechnetate uptake of the kneejoint. Mice were sedated with chloralhydrate 
(intraperitoneally) and injected subcutaneously in the neck region with 10 μ(ϋί 
T c . After 20 min, radioactivity was assessed by measuring both knees in a 
fixed position. Joint swelling was expressed as the ratio of the WmTc-uptake in 
the left and right knee joint.24 
Histology 
On day 3 and 7 after arthritis induction groups of at least 5 mice were killed. 
Knee joints were dissected and processed for histology, as described 
previously.25 Whole kneejoint sections (6 μπί) were prepared and stained with 
hematoxylin/eosin. Arthritis was scored semiquantitatively in a standarised 
frontal section of the kneejoint which included menisci, cruciate ligaments and 
the patella. Extent of cellular infiltration of synovial tissue, and cellular 
exudate in the joint space were graded on a scale ranging from 0 (no cells) to 
3 (severe infiltrate and exudate). 
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Statistics 
Results are expressed as mean (+ sd). The Wilcoxon's Rank Sum test was 
used to test statistical significance. Differences were statistical significant when 
p-values were less then 0.05 (*) 
RESULTS 
Induction of tolerance by oral feeding 
The possibility of inducing tolerance was studied by feeding 25 mg of a 
protein 7 days before immunisation. Immunity was tested on day 14 with an 
ear challenge test and measured at 4, 24, and 48 h. Feeding of native OVA 
and BSA showed a highly significant reduction in ear swelling (at 48 h) of 
73% and 43%, respectively. Modified proteins, which were cationic, could 
not induce any suppression (figure 1). 
L/R ratio 
1.80 
1.70 
1.60 
1.50 
1.40 
1.30 -
1.20 -
1.10 
1.00 
BSA mBSA aBSA OVA 
Antigen 
aOVA 
Figure 1. The capacity of different antigens to induce tolerance after a single 
feeding of 25 mg, 7 days before immunisation (hatched bars). Control groups 
received 25 mg casein (black bars). On day 14, ear thickness was measured at 
48 h (8 mice per group). Values are expressed as L/R ratios (mean ± sd). 
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The tolerance induction was not observed on B-cell level; Ab-titres were 
almost equal for treated and control groups (table 1). Ear swelling as measured 
at 4 h was similar for all groups (data not shown). 
Table 1. Effect of feeding different antigens on Ab-titres (day 18). 
Dilution3 
Antigen control (casein) 25 mg antigen 
BS A 2048 2048 
mBSA 2048 1024 
aBSA 2048 2048 
OVA 1024 512 
aOVA 4096 4096 
3
 Ab-titre is expressed as the dilution where the extinction reaches 
half the maximum value (mean of 4 different mice per group). 
Standard deviations never exceed one dilution step. 
The difference in tolerance induction for native and cationic proteins was 
further studied by comparing OVA with aOVA. It is well known that tolerance 
induction depends on the administered dose.1415 Feeding OVA, in a dose 
ranging from 0.5 to 25 mg, resulted in a dose-dependent suppression (figure 2). 
Figure 2. Tolerance induction (DTH, 
48 hr) by feeding a dose range of 
OVA. Control group received 25 mg 
casein. Values are expressed as the 
mean (± sd) of UR-ratios on day 14 
of 8 mice per group. 
L/R ratio 
conimi 0 5 5 12 5 25 
OVA (mg) 
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The Ab-titres were tested 17 days after immunisation in an ELISA. Both 
control and treated groups showed equal anti-OVA titres: 50% of the maximal 
extinction was reached at a 640 times dilution. In case of aOVA (Figure 3) no 
suppression could be induced in the dose-range tested (0.05-50 mg). 
L/R ratio L/R ratio 
control 0.5 5 12.5 25 control 0.05 0.2 5 50 
aOVA (mg) aOVA (mg) 
Figure 3. Lack of tolerance induction (DTH) by feeding a dose-range of 
aOVA: 0.5 to 25 mg (a), 0.05 to 50 mg (b)(hatched bars). Control groups 
received 25 or 50 mg casein, respectively (black bars). On day 14, DTH-
values were measured at 48 h, and represent the mean (± sd) of 8 mice per 
group. 
Two alternative possibilities to induce a state of tolerance were investigated. 
First, cross-studies were carried out, consisting of feeding OVA before aOVA-
immunisation or feeding aOVA before OVA-immunisation. In a second 
attempt, antigens were administered i.V.. Table 2 summarizes the cross-
studies. In a set of OVA-immunised mice (groups I-III) similar DTH-values 
were measured after challenge with 50 ^g OVA or 10 μg aOVA, respectively. 
This indicates that OVA-specific epitopes, relevant for DTH, are still present 
on aOVA. The DTH was markedly suppressed after oral feeding of OVA 
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(group II), irrespective of the test antigen used. Ab-levels were equal (data not 
shown). Feeding with aOVA did not cause any suppression (group III). In a 
second set of experiments (groups IV and V) OVA was found to be a poor test 
antigen in aOVA-immunised mice. These animals may posses strong T-cell 
immunity against aOVA, and only a weak immunity against OVA-specific 
epitopes. Feeding with OVA caused only partial suppression of the DTH. No 
differences were measured in Arthus-reaction (table 2) and Ab-titres. It is 
tempting to speculate from the DTH data, obtained with OVA and aOVA, that 
only the OVA-specific part is suppressed (see column δ, table 2). This may 
imply that suppressive epitopes on OVA are irrelevant for regulation of 
aOVA-immunity. 
Table 2. Orally induced tolerance (DTH) in cross-studies. 
Group Orally fed Immunisation DTH (L/R ratio) δ* 
(η = 8) Ag (day-7) (day 0) 10
 Mg aOVA 50 ^g OVA 
control0 
OVA 
aOVA 
control 
OVA 
OVA/CFA 
OVA/CFA 
OVA/CFA 
aOVA/CFA 
aOVA/CFA 
1.67 ± 0.19 
1.38 ± 0.09' 
1.59 ± 0.12 
1.90 ± 0.11 
[1.76 ± 0.72/ 
1.66 ± 0.14" 
[1.63 ± 0.15] 
1.73 ± 0.75 
1.29 ± 0.0& 
1.68 ± 0.33 
1.33 ± 0.13 
[1.11 ± 0.05] 
1.15 ± 0.04~ 
[1.13 ± 0.07] 
a
 'δ' represents the difference between the DTH-values ofaOVA and OVA. 
ь
 Control mice received 25 mg casein. 
c
 Values enclosed in brackets represent DTH-values measured at 4 h. 
Induction of tolerance by intravenous administration 
In the next attempt to achieve a state of tolerance, antigen was administered 
i.V.. Six days before immunisation, antigens were injected in the tail vein. 
Figure 4a shows that a low amount of OVA (25 μg) was sufficient to induce 
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significant suppression. In contrast, a high dose of aOVA (500 μg) was 
required to achieve a moderate suppression (figure 4b). 
L/R ratio L/R ratio 
2.00 
1.80 
1.60 
1.40 
1.20 
1.00 
control 0.025 0.1 0.5 1.0 
OVA (mg) 
2.00 
.80 
1.60 
1.40 
1.20 
1.00 
control 0.05 0.1 0.5 
aOVA (mg) 
Figure 4. Tolerance induction (DTH) by i.v. administration of a dose-range 
of OVA (a) and aOVA (b)(hatched bars). Control groups received 1 mg or 0.5 
mg casein, respectively (black bars). On day 14, DTH-values were measured 
at 48 h and represent the mean (± sd) of 8 mice per group. 
The possibility to induce suppression by i.v. administration of aOVA was 
further studied in a chronic T-cell dependent animal model of arthritis [antigen 
induced arthritis (AIA)]. High dosages, up to 2.5 mg aOVA, were tested in an 
attempt to achieve suppression of the arthritis. Tables 3a, and 3b show the 
joint swelling and the additional histology of these experiments, respectively. 
High dosages of aOVA were able to suppress the arthritis. When 2.5 mg was 
used, suppression was clear in joint swelling as well as in histological 
findings. Administration of 1.0 mg or 0.25 mg aOVA slightly reduced joint 
swelling, and at day 7 the histological data showed suppression of the arthritis. 
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Our data indicate that the cationic antigen aOVA may induce suppression, 
provided that extremely high i.v. doses were used. Small effects on DTH may 
nevertheless translate in marked suppression of chronic processes. 
Table 3a. I.v. induced tolerance in an AIA (joint swelling). 
I.v. administered Immunisation 99mTc-uptake (R/L ratio)3 
antigen (day -6) (day 0) day 3 day 7 
control (casein)" aOVA/CFA 1.57 ± 0.14 1.25 ± 0.08 
2.5 mg aOVA aOVA/CFA 1.15 ± 0./6* 1.12 ± 0.0? 
1.17 ± 0.77 
1.11 ± 0.0? 
1.0 mg aOVA aOVA/CFA 1.37 ± 0.0T 
0.25 mg aOVA aOVA/CFA 1.40 ± 0.17* 
a
 Measure for the joint inflammation as described in Materials and methods. 
b
 Number of mice per group used is ten. 
Table 3b. I.v. induced tolerance in an AIA (histology). 
I.v. administered Infiltrate3 Exudateb 
antigen (day -6) day 3 day 7 day 3 day 7 
control (casein) 
2.5 mg aOVA 
1.0 mg aOVA 
0.25 mg aOVA 
2.Ie 
0.8* 
1.4 
1.4 
2.3 
0.7* 
0.7* 
1.2* 
2.3 
1.0 
2.0 
1.6 
0.8 
0.2* 
0.2* 
0.3* 
a
 Number of cells in the synovial tissue (scale from 0 to 3). 
b
 Number of cells in the joint space (scale from 0 to 3). 
c
 Number of mice per group used is five. 
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DISCUSSION 
The results presented here demonstrate that a single administration (i.v. or 
oral) of the native proteins OVA and BSA is very effective in the induction of 
tolerance. This in contrast to the effects of the modified cationic proteins 
aOVA, mBSA and aBSA, where no suppression could be induced. 
Suppression was only seen on T-cell level, whereas negligible differences were 
measured on Ab-levels. Several reports describe a decrease in Ab responses 
after oral feeding.5·62637 In some cases, multiple feedings or high doses of 
antigen are needed.1028 Contradictions in the ability to get suppression on Ab-
level can be explained by differences in susceptibility between mouse strains to 
induce a state of tolerance. C57Bl/6-mice (H-2b) seem to be resistant to this 
type of tolerance induction.2931 A single feeding of 25 mg OVA, BSA, aOVA, 
aBSA or mBSA was in our hands not sufficient to get a clear drop in Ab-titre. 
By contrast Muckerheide et α/.32 showed that oral administration of BSA gave 
a decrease on Ab-level, whereas feeding aBSA even led to a certain 
enhancement. We never observed enhancement of the Ab-titre. The route of 
immunisation and the strain of mice used may account for the observed 
differences. Muckerheide immunised intraperitonally with a mixture of antigen 
and aluminium hydroxide gel. We immunised subcutaneously with antigen 
emulsified in CFA. This may have consequences for the degree of immunity 
and the capacity to influence the immunological balance. 
Differences in the induction of tolerance on T-cell level between native 
proteins and the modified cationic proteins were clear and consistent. Feeding 
aOVA in a dose-range from 50 /ig up to 50 mg could not induce any 
suppression in aOVA-immune mice. This in contrast to feeding OVA, where 
a significant suppression was seen by administering 0.5 mg. Cross-studies 
show that the inability of inducing tolerance by feeding aOVA was not only 
seen in aOVA-immune, but also in OVA-immune mice. The degree of 
cationicity may account for differences in absorbance of antigens by the gut. 
Therefore cationic antigens may not reach the circulation. However, Domen et 
α/.33 showed clear effects on Ab-titres when a single dose of 10 or 50 mg 
aBSA was feeded. Furthermore Lens et α/.34 showed that distinct levels of 
antigen in the circulation were reached after feeding 20 mg mBSA. 
We conclude from our studies that oral administration of aOVA is incapable to 
induce an OVA- or aOVA-specific suppressor-circuit. A possible explanation 
for the lack of tolerace induction is that amidation may create new epitopes, 
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capable of stimulating the The,per-circuit. This may result in a changed 
competition in antigen presentation or disappearance of suppressive epitopes. 
Other studies demonstrated that competition of epitopes on class II MHC-
molecules on antigen presenting cells (APC) is a phenomenon that exists not 
only in vitro, but also in vivo.35'37 Suppressive epitopes have been determined 
for some proteins, i.e. BS A39·"0 and hen egg lysozyme41·42. Suppressor 
determinants have also been found for autoantigens like MBP. Suppression of 
the encephalomyelitis was more complete after feeding a nonencephalitogenic 
fragment of MBP than after administering an encephalitogenic fragment.6,43 
Suppressor cells have often been described as the mechanism for tolerance 
induction.2-6"9 This seems, in case of protein antigens, a more plausible 
explanation than an anergic state of T-helper cells or clonal deletion.910 
The incapability of aOVA to induce tolerance could also be a consequence of 
a strong and potent aOVA-immunity. Muckerheide et al.u suggested that 
cationisation of an antigen produces a molecule that preferentially stimulates 
help rather than suppression. A cationic protein would be more efficiently 
presented to an APC than the native protein. This phenomenon could result in 
a disturbed balance between helper- and suppressor-cells. It may therefore be 
hard to modulate an immunity induced by cationic antigens. 
The results of the i.v. studies indicate that the i.v. administration of an antigen 
is very effective in inducing tolerance. Already 25 μζ of OVA was sufficient 
to reach a clear state of suppression. This correlates with results from 
Thompson and Staines14, who showed that i.v. administration of an antigen 
was more effective in the induction of tolerance than oral feeding. It is likely 
that the way the immune system is triggered differs. Oral feeding may trigger 
the lymphoid system via the GALT, whereas i.v. administration may have its 
effect via the systemic lymphoid tissues. 
In case of aOVA, a marginal suppression was induced after administering 500 
μg of aOVA i.v.. Such a high concentration will never be reached in the blood 
after oral antigen feeding. The same kind of results were obtained when aOVA 
was tested in a chronic T-cell dependent model for arthritis. The dose of 
aOVA needed to get suppression was 10 times higher than the dose of OVA. 
It is important to be aware of the difference between native proteins and their 
cationic derivatives to induce a CMI suppression. The chance to modulate an 
immune status or an arthritis by this type of immunointervention may be 
highly dependent on the nature of the antigen involved. 
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CHAPTER 4 
CATHEPSIN D BUT NOT CATHEPSIN В RELEASES T-CELL 
STIMULATORY FRAGMENTS FROM LYSOZYME THAT ARE 
FUNCTIONAL IN THE CONTEXT OF MULTIPLE MURINE CLASS II 
MHC MOLECULES 
Johannes M. van Noort & Marike J.M. Jacobs 
European Journal of Immunology, in press 
SUMMARY 
In this study, the major endosomal/lysosomal proteases cathepsin D and 
cathepsin В were tested on their ability to release T-cell stimulatory peptides 
from HEL in vitro. Whereas neither enzyme could cleave unreduced HEL 
under mild conditions, reduced HEL was readily cleaved by cathepsin D but 
not by cathepsin B. Instead, cathepsin В was found very active in the trimming 
of HEL peptides after their release by cathepsin D. 
Following HPLC fractionation, cathepsin D-released HEL fragments were 
screened for recognition by HEL-specific Τ cells from three strains of mice, 
viz. B10.A (H-2a), C57BL/6 (H-2b) and Balb/c (H-2d). Peptides in a large 
number of different HPLC fractions triggered significant T-cell responses in all 
three strains. Interestingly, the response profiles of Τ cells from the three 
different strains showed marked similarities. Also, several individual synthetic 
HEL sequences corresponding to selected cathepsin D-released fragments were 
recognised by murine Τ cells in the context of all three MHC haplotypes tested. 
Our data suggest that cathepsin D rather than cathepsin В may play a central 
role in the initial release of HEL fragments during endosomal/lysosomal 
processing. The relatively long HEL fragments as released by cathepsin D, 
containing about 20-30 amino acid residues, are significantly more 
promiscuous in murine class II MHC binding than the shorter synthetic HEL 
sequences previously employed by others for the delineation of HEL epitopes. 
Extensive documentation of HEL epitopes in previous investigations indicate 
that this promiscuity cannot be explained by assuming longer peptides to 
simply contain additional epitopes. Rather, an increased peptide length by 
itself appears to promote promiscuous MHC binding. 
INTRODUCTION 
Intracellular processing including proteolysis is a general prerequisite for 
antigen presentation by MHC molecules.' Evidence has been reported for an 
intracellular rather than extracellular association of processed antigen with 
newly synthesised class II MHC molecules.2 Antigen processing and removal 
of invariant chains from newly formed class II molecules may even be 
colocalised and occur simultaneously.3 Thus, antigen fragments will most 
likely compete for binding to class II molecules very shortly after their release 
from nominal antigen and prior to extensive degradation by processing 
enzymes from which they are, in fact, protected by MHC binding.4 
The proteolytic machinery responsible for the generation of peptides presented 
by MHC class II molecules resides within the endosomal/lysosomal 
compartment.1"3 A variety of studies have implicated endosomal/lysosomal 
proteases such as cathepsin D, cathepsin В and cathepsin E in processing of 
selected model antigens.vw In addition, qualitative evidence has been reported 
to suggest a relationship between the selectivity of cathepsin D and the peptide 
binding requirements of class II MHC molecules in general.9"11 The available 
evidence indicates that although no single processing enzyme can be held 
responsible for all peptide bond cleavages during antigen processing, initial 
cleavage of antigen may well be dominated by the most abundant proteases 
and especially by cathepsin D. 
For the model antigen HEL, pioneering studies have led to the identification of 
helper Τ cell epitopes for various murine class II MHC backgrounds. , 2 1 3 a n d 
rep»™« herein
 B y t e s t ¡ n g т _ с е ц recognition of short synthetic HEL peptides (up to 
maximally 20 residues), the different class II MHC haplotypes have been 
shown to present different portions of the HEL molecule. Also, a number of 
naturally processed HEL fragments have been identified following elution 
from murine class II MHC molecules.1415 However, no biochemical analyses 
Cathepsin D-released T-cell fragments 55 
have been reported describing which sequences could possibly be released 
from HEL during the initial steps of endosomal/lysosomal proteolysis. 
In this study, we examined the potential of both cathepsin D and cathepsin B, 
representing the two major endosomal/lysosomal proteases, in releasing HEL 
fragments under mild conditions in vitro. While cathepsin D could rapidly 
release a number of different HEL fragments, cathepsin В completely failed to 
do so under the same conditions and was found only able to trim down HEL 
peptides after their release. Interestingly, several cathepsin D-released HEL 
fragments turned out to be recognised by murine Τ cells in the context of 
more than one class II MHC haplotype. Most of the peptides predominantly 
released by cathepsin D are between about 20 and 30 amino acids long. Our 
data suggest that these relatively large initial products of class II-associated 
processing may be more promiscuous than the relatively short synthetic 
peptides that are usually employed for epitope mapping. This finding may 
have implications for the perspective of using synthetic peptides for 
vaccination or immunotherapy in populations with multiple class II MHC 
backgrounds. 
MATERIAL AND METHODS 
In vitro degradation of HEL by cathepsin D and cathepsin В 
Prior to mild treatment with either protease, HEL (Boehringer, Mannheim, 
Germany; final concentration 20 mg/ml) was reduced by treatment with 2.5 M 
/3-mercaptoethanol in 8 M urea in water for 2 h at 37°C. The protein solution 
was exhaustively dialysed against 0.05% (vol/vol) acetic acid in water under a 
nitrogen atmosphere at room temperature and used immediately for the 
digestion experiments. Dialysis was performed against diluted acetic acid since 
in our hands, reduced but unmodified HEL remains soluble only at pH below 
6.5. 
Reduced HEL (2 mg/ml final concentration) in 80 mM NaAc/HAc pH 5.0 was 
supplied with 0.65 U/ml purified cathepsin D or 0.65 U/ml purified cathepsin 
В (obtained from Sigma Chemical Co., St. Louis, MO, USA) and incubated at 
37°C for varying periods of time. Proteolysis was stopped by the addition of 
Tris-HCl pH 9.0 to a final concentration of 300 mM and of acetonitrile to a 
final concentration of 50% (vol/vol). Under these conditions, residual intact 
HEL precipitates and can be removed by centrifugation for 10 min at 3000 g; 
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the resulting supernatant was freed from acetonitrile by nitrogen perspiration 
and analysed by reversed phase HPLC. The digest was applied onto a 
Lichrosorb C18 column (Merck, Darmstadt, Germany) and eluted at 1 ml/min 
with a gradient of acetonitrile in 0.1% (vol/vol) trifluoroacetic acid ranging 
from 5-20% over the first 5 min, 20-40% over the next 30 min and from 40-
60% over the final 10 min. The eluate was monitored at 214 nm. 
For use as a substrate for cathepsin B, the set of HEL fragments as obtained 
after a 30-min digestion with cathepsin D was first passed over a reversed 
phase column in order to remove all residual cathepsin D and any intact HEL 
and subsequently lyophilised. The lyophilised digest was taken up in 80 mM 
NaAc/HAc pH 5.0 to a total peptide concentration of 2 mg/ml and supplied 
with 0.65 U/ml cathepsin B. Proteolysis at 37°C was stopped at different points 
in time by the addition of Tris-HCl pH 9.0 to a final concentration of 300 mM. 
Identification of cathepsin D-released HEL fragments 
The fragments formed after a 30-min treatment of HEL with cathepsin D were 
fractionated by reversed phase HPLC and collected in 1-ml fractions as 
described above. Aliquots of each individual fraction were lyophilised and 
used as antigen in the T-cell assays while another aliquot was further 
fractionated by reversed phase HPLC in order to resolve individual peptides 
present in each fraction. Purified peptides were identified by amino acid 
composition analysis as described previously.9 The method used for amino 
acid analysis does not allow the quantitation of tryptophan or cysteine 
residues. Therefore, UV absorption spectra were taken of all peptides in order 
to identify tryptophan-containing peptides. In order to identify cysteine-
containing peptides, a parallel digestion was performed of reduced and 
carboxymethylated HEL, allowing the detection and quantitation of 
carboxymethyl-cysteine which is stable upon acid hydrolysis. The data 
obtained indicate that carboxymethylation of HEL does not affect the sites of 
cleavage by cathepsin D (data not shown). 
Recognition of cathepsin D-released HEL fragments by murine LNC 
Mice were immunised in the footpads of forelegs and subcutaneously in the 
flanks with 200 f¿g HEL emulsified in complete Freunds adjuvant (CFA; 
Difco, Detroit, MI, USA). In addition, 2xl09 heat-killed Bordetella pertussis 
organisms (National Institute of Public Health, Bilthoven, The Netherlands) 
were administered intraperitoneally. Seven days later, animals were boostered 
in the flanks with 150 μg HEL in CFA. Fourteen days after boostering, mice 
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were sacrificed and draining lymph nodes were removed aseptically. A single 
cell suspension was prepared by gentle teasing in a sterile infusion system 
(NBPI bv., Emmer-Compascuum, The Netherlands). Cells were washed and 
enriched for Τ cells by nylon wool passage; LN cells were adjusted to 
2xl06/ml. As antigen-presenting cells, naive irradiated syngeneic spleen cells 
were used. Spleens were removed aseptically, single cell suspensions were 
prepared and erythrocytes were lysed with 0.16 M NH4C1; 0.17 M Tris-HCl, 
pH 7.2 for 1 min at room temperature. Cells were washed three times and 
adjusted to a concentration of lxl07/ml. Culture medium was RPMI-1640 
Dutch modification (Flow Laboratories, Zoetermeer, the Netherlands) supplied 
with 20 mM glutamine, 10 mM pyruvate, 0.5 mM /3-mercaptoethanol and 2% 
homologous serum. 
Proliferative responses of LN cells were determined to various antigens upon 
culturing in a round-bottom 96-well microtiter plate (Costar, Cambridge, MA, 
USA). To a 100 /xl solution of antigen, 50 μΐ LN cells (2x10s cells/ml) and 50 
μΐ APC ( 1 χ 107 cells/ml) were added. After 72 h of culture in a humidified 
stove at 37°C and 5% C0 2, 1 μΟί [3H]-thymidine was added to each well. 
Sixteen hours later, [3H]-thymidine incorporation was determined in a 
betaplate liquid scintillation counter (LKB, Bromma, Sweden). Stimulation 
indices were calculated from the ratio of proliferative responses in the 
presence of antigen to that in the absence of antigen. 
Peptide synthesis 
Peptides were synthesised as free acids on an automated Miliigen 9050 
Continuous Flow Synthesiser (millipore Co, Milford, MA) by the solid phase 
method of Merrifield using Fmoc chemistry as described by Zegers et α/.16 The 
cleaved and deprotected peptides were purified by reversed-phase HPLC to a 
purity of minimally 95% based on the absorption profile at 214 nm. Yield and 
purity of peptides was checked by amino acid analysis as described previously.9 
RESULTS 
Mild cleavage of HEL with cathepsin D and cathepsin В 
HPLC analysis of HEL digests obtained during a 1-h treatment with either 
purified cathepsin D or purified cathepsin В revealed that whereas unreduced 
HEL could not be cleaved by either enzyme (data not shown), reduced HEL 
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was rapidly degraded by cathepsin D but not by cathepsin В (figures 1A and 
IB). Our observation that HEL needs to be reduced before any peptide can be 
released by a processing enzyme in vitro is in line with previous data 
illustrating a corresponding requirement for reduction during processing in 
vivo.16,17 The HPLC profiles of peptides released by cathepsin D remained 
stable over the first hour of degradation. 
HEL treatment with 
cathepsin D 
В 
HEL treatment with 
cathepsin В 
I 
15 min 
V 
treatment of HEL fragments 
with cathepsin В 
0 |!П^А|Ш ι 
30 min 15 min l АДА. 
t 45 min 3 0 m !?jUuL 
60 min 60 min ""JjiL 
Figure 1. Reduced HEL was treated for varying periods of time with purified 
cathepsin D (A) or cathepsin В (В) at pH 5.0 and the resulting digests were 
analysed by reversed phase HPLC. Also the set of peptides as obtained after a 
30-min treatment of HEL with cathepsin D was used as a substrate for 
cathepsin В under the same conditions (C). The HPLC traces ilústrate rapid 
production of a stable set of fragments by cathepsin D but not by cathepsin В 
which, instead, is well able to degrade most, if not all HEL peptides once they 
are released by cathepsin D. 
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Apparently, most initially released HEL fragments were fairly resistant 
towards continued degradation by cathepsin D. In contrast to its inability to 
release any fragments from reduced but intact HEL, cathepsin В was very 
active in the degradation of a set of cathepsin D-released HEL fragments 
(figure 1С). The HPLC profile of the digest was very much altered by 
cathepsin В within minutes indicating significant degradation of the majority of 
peptides. No attempts were undertaken to characterise the products formed 
after peptide degradation by cathepsin B. It is likely that an exopeptidase 
activity of the enzyme is responsible for the peptide degradation illustrated in 
figure 1С, in line with a previous report on the cleavage of myoglobin.9 
The relatively stable set of fragments formed upon a 30-min digestion of HEL 
with cathepsin D (see figure 2) were HPLC-fractionated and the contents of 
each fraction were further resolved upon additional HPLC steps, purified and 
identified by amino acid analysis as described under Materials and Methods. 
0 2 AU214 
Figure 2. HPLC analysis of a cathepsin D released set of HEL fragments. 
Reduced HEL was treated with purified cathepsin D and the resulting digest 
was fractionated by reversed phase HPLC as described in Materials and 
Methods. Figure 2 shows the HPLC trace as monitored at 214 nm. The 
predominantly released fragments are indicated by numbered peaks; their 
sequences are given in table I. 
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Results of these analyses are summarised in table 1. Molar yields of major 
fragments released under the mild conditions employed ranged from 0.1 -
0.2%. Based upon these data, maximal concentrations of predominant HEL 
fragments as used in the assays described below with murine LNC were 
calculated to range between 5 and 10 μg/ml. 
Table 1. Identification of HEL fragments released by mild treatment with 
cathepsin D 
peak no.a 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
sequence 
60-62 
109-123 
38-59 
32-59 
35-56 
41-56 
124-129 
9-28 
32-62 
31-62 
1-28 
1-30 
109-129 
63-75 
1-31 
63-83 
yield (nmoI)b 
1.3 
3.5 
1.8 
3.0 
1.3 
0.9 
0.7 
4.5 
7.5 
1.8 
4.9 
4.7 
4.9 
3.1 
2.6 
contained in HPLC fraction 
unidentified mixture of peptides 
2.4 
unidentified mixture of peptides 
6 + 7 
12+13 
14+15 
19 
19 
20+21 
21 
21 
24 + 25 
28 
29 
30 + 31 
32 
33 
33 + 34 
37 
a
 Peak numbers refer to figure 2 which shows the HPLC trace of the cathepsin 
D-released set of HEL fragments. 
b
 Yields as given in Table 1 are based upon amino acid analysis of individual 
peptides as purified from a 20 % aliquot of the original HPLC fraction. This 
aliquot contains fragments generated from 4 μτηοΐ HEL. The remaining 80% of 
the HPLC fraction was used as antigen in the proliferation assays (figure 3). 
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It is of interest to note that the predominant HEL fragments released by 
cathepsin D are fairly long fragments and contain between about 20 and 30 
amino acids. The set of cathepsin D-released HEL fragments identified in this 
study covers most of the protein molecule. No peptides, however, could be 
detected that represent the sequence between residues 84 and 108. Possibly, 
this region is rapidly digested into many small and hydrophillic fragments that 
preclude their purification by reversed phase HPLC. The very same region 84-
108 has previously been identified by others as being poor in class II-restricted 
epitopes.1213 
Recognition of cathepsin D-released HEL fragments by bulk Τ cells 
The HEL digest as obtained after mild treatment with cathepsin D was 
fractionated by reversed-phase HPLC and each individual HPLC fraction was 
tested for recognition by HEL-specific Τ cells from three different strains of 
mice, viz. B10.A (H-2a), C57BL/6 (H-2b) and Balb/c (H-2d). Previously 
reported data have shown these strains of mice to select different synthetic 
HEL peptides for presentation to murine helper Τ cells.1213 and referencet *"Kia 
However, peptides used in those studies were between 10 and 20 amino acids 
and, thus, consistently shorter than the peptides released by cathepsin D. 
Moreover, chemical blocking of peptides at their N- or C-termini has 
frequently been employed (e.g. in reference 12) which could affect a peptide's 
MHC binding properties in some cases. 
Figure 3 illustrates proliferative responses of LNC from three different strains 
of mice to the HPLC-fractionated HEL digest generated by cathepsin D. The 
data reveal recognition of many different HPLC fractions, which is especially 
clear for Τ cells from the high-responding Balb/c mice. These Τ cells display 
significant proliferative responses to virtually every fraction beyond #12. 
Although some differences do occur in the magnitude of responses to HPLC 
fractions for the different strains of mice, it is striking that predominant 
responses are directed to the same HPLC fractions in several cases. Fractions 
24/25 (containing the HEL fragment 32-62), fraction 32 (fragment 109-129), 
fraction 33/34 (fragments 1-31 and 63-75) and fraction 37 (fragment 63-83) 
trigger strong T-cell responses in all three strains of mice. It should be noted 
that the maximum dose of antigen used in these experiments is 5-10 ^g/ml, 
which is likely to be suboptimal for triggering bulk Τ cells under these 
conditions. HPLC fractions were also tested in 1/2.5 and 1/10 dilutions; 
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proliferative responses found were consistent with the dilutions used and 
revealed no anomalies. 
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Figure 3. HEL was treated with cathepsin D for 30 min and the resulting 
digest was fractionated by reversed phase HPLC. To each fraction, 
proliferative responses were determined of LN cells from HEL-immunised 
B10.A (H-T), C57BL/6 (H-?) or Balh/c (H-21) mice. Final concentrations of 
peptides in the assay ranged from 5-10 \iglml for the most dominant species. 
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In order to further examine whether or not selected HEL fragments as released 
by cathepsin D could be presented by class II MHC molecules from different 
mouse strains, cathepsin D-released HEL-sequences 1-31, 32-62, 63-83 and 
109-129 were synthetically prepared. Thus, these HEL fragments were 
prepared in a way that excluded any contamination by other HEL sequences as 
might have occurred during HPLC fractionation. With one exception, Τ cells 
from all three strains of mice displayed low, but significant responses to all 
peptides tested (table 2). The relatively low proliferative responses by bulk Τ 
cells to single synthetic HEL peptides are in line with similar findings by 
others. Also experimental variation may partly explain why the antigen-
specific proliferation documented in table 2 is lower than that illustrated in 
figure 3. 
Table 2. Proliferative bulk responses of HEL-primed Τ cells 
against synthetic versions of cathepsin D-released fragments. 
antigen 
1-31 
32-62 
63-83 
109-129 
HEL 1 μg/ml 
HEL 25 
HEL ЮС 
Mg/ml 
) μg/ml 
C57BL/6 
3.3 
2.6 
1.8 
2.7 
2.3 
11.1 
35.0 
Balb/c 
5.6 
5.8 
3.6 
4.8 
1.7 
11.6 
36.1 
BIO. 
7.0 
4.3 
2.3 
3.1 
1.3 
5.9 
33.0 
footnote: Proliferative responses, given as stimulation index, were 
assayed at the concentration of each peptide that was optimal for 
responses. These concentrations ranged between 1 and 25 μg/ml. 
Background proliferation for C57BL/6 cells was ¡03 cpm.for 
Balb/c cells 87 cpm and for BIO. A cells 65 cpm. 
No gross differences were observed in the responses against peptides that 
contain documented helper T-cell epitopes for a particular strain as compared 
to those against the other peptides. For example, Τ cells from Balb/c mice 
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respond well to the cathepsin D-released fragment 109-129 (SI = 4.8) that 
contains the well-documented 109-115 epitope for H-2d.12·13 For the same 
strain, however, comparable responses were found against the fragments 1-31 
(SI = 5.6), 32-62 (SI = 5.8) and even against 63-83 (SI = 3.6). Moreover, 
the apparent hierarchy in proliferative responses to the four selected fragments 
turned out similar among the three strains. In all cases, high responses were 
found to the fragment 1-31 and low responses to 63-83 whereas intermediate 
proliferation occurred to 32-62 and to 109-129. 
DISCUSSION 
In this study, we have investigated the abilities of purified cathepsin D and 
cathepsin В to release T-cell stimulatory peptides from HEL in vitro. In line 
with previous findings, release of HEL fragments upon proteolysis was only 
observed after reduction of the protein.1718 Treating reduced HEL with 
purified preparations of either cathepsin D or cathepsin В revealed that only 
cathepsin D was able to effectively degrade the protein into a series of 
different fragments, together covering over 90% of the polypeptide chain. 
While cathepsin В did not cleave intact HEL, it was very active in the 
degradation of shorter HEL fragments (figure 1С). The same lack of 
endopeptidase activity and display of high exopeptidase activity by cathepsin В 
has previously been observed using myoglobin as a substrate.9 When taken 
together, these data are consistent with a pivotal role of cathepsin D in the 
initial steps of HEL cleavage during endosomal/lysosomal processing. 
In the present study, degradation conditions were kept mild to allow an only 
limited extent of cleavage. This approach was taken since all available 
evidence indicate that the capture of antigen fragments by newly synthesised 
class II MHC molecules within APC probably occurs very rapidly after the 
first steps of antigen denaturation and cleavage and involves only partly 
processed antigen rather than extensively cleaved material.rev'ewcd " 1 9 2 0 The data 
in figure 2 show that degradation of no more than 0.2% of the available HEL 
molecules by cathepsin D is sufficient to release a large variety of T-cell 
stimulatory peptides functional in conjunction with multiple murine MHC class 
II molecules. Previously, Collins et al. reported failure of the hybridoma 3A9, 
specific for the HEL sequence 54-61 in the context of I-Ak to recognise a 
cathepsin D-generated digest of HEL in which about 40% of HEL was 
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degraded.17 The present data show that under mild conditions, cathepsin D 
does release the fragments 31-62 and 32-62 which contain all residues between 
54 and 61 required for stimulation of 3A9 in the context of T-AV2·2 1·2 2 
However, continued degradation will result in cleavage between residues 59 
and 60 (table 1) which will abolish recognition of the peptides by 3A9 by 
removing the essential residues 60 and 61. Thus, prolonged in vitro 
degradation of HEL with cathepsin D as applied by Collins et al. destroys a 
major epitope that is generated by the same enzyme under more mild 
conditions, the latter of which is expected to approach the in vivo situation 
more closely.19·20 
Also other immunodominant epitope sequences were found to be represented 
in the digest as produced by cathepsin D. A PEPSCAN delineation of HEL 
epitopes presented by the mouse strains used in our study has been reported by 
Gammon et al..12 That study revealed an immunodominant epitope for Balb/c 
mice at residues 109-115, which is present in the fragments 109-129 and 109-
123. Epitopes for Balb/b mice (H-2b) were mapped at 38-45, at 77-85 and at 
83-90. Only the latter minor epitope could not be recovered from the digest in 
the present study. The core sequence of the major epitope recognised by 
В10.A (as well as by H-2k) mouse strains was identified as residues 54-61. 
These residues are present in the form of fragments 31-62 and 32-62. This 
comparison illustrates that mild treatment of HEL with cathepsin D is 
sufficient to release fully intact versions of the immunodominant helper T-cell 
epitopes of HEL. 
Previously, naturally processed HEL fragments eluted from I-Ed and I-Ak 
molecules, respectively, have been characterised.1415 In the set of I-Ed-eluted 
HEL fragments, two or three peptides with an apparent M
r
 of about 2000 
representing the 109-116 epitope were detected.14 This molecular mass is 
consistent with that of the cathepsin D-released fragment 109-129 or slightly 
truncated versions of this sequence (table 1). Full sequencing of a set of I-Ak-
eluted fragments that contain the 52-61 epitope indicated that about 70% of the 
recovered peptide material had Trp-62 as the C-terminal residue.15 This 
boundary coincides with a predominant site of initial cathepsin D cleavage 
(table 1). However, I-Ad eluted peptides were clearly shorter than the 
presently identified fragments. Additional trimming of the initial products of 
processing, even after binding to MHC molecules, may well explain such 
differences.1920 Not only other endosomal/lysosomal proteases such as 
cathepsin В but also extracellular or surface-bound proteases may contribute to 
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continued partial degradation of МНС-bound HEL fragments, as has been 
demonstrated for class I МНС-associated peptides.23 
Recognition of HPLC fractionated cathepsin D-released HEL fragments by 
bulk Τ cells from HEL-immunised mice reveals T-cell recognition of a large 
number of different fragments, consistent with the presence of previously 
identified helper epitopes within the series of fragments tested. The most 
striking observation in the present study, however, is that bulk Τ cells from 
three different strains of mice displayed major proliferative responses to the 
same HPLC fractions. It should be noted that each fraction may contain 
mixtures of different minor peptides accompanying the predominant peptide 
components listed in table 1. Thus, the responses observed to any particular 
fraction could in principle be directed to different minor peptide components 
rather than to the predominant ones. Yet, the tenet of T-cell responses in the 
three different strains of mice being directed at completely different 
immunodominant sequences is difficult to reconcile with the data represented 
in figure 3 since this would imply co-elution upon reversed-phase HPLC of 
essentially different HEL fragments in all cases. Instead, we prefer to explain 
our observations by assuming significant Τ cell responses to similar or 
strongly overlapping HEL sequences in the three different strains of mice, 
much more than previously documented.12 imdr' :f<:rencee,hercin. We believe that this 
apparent promiscuity may be explained by the fact that the HEL fragments 
tested here are consistently longer than synthetic peptides previously employed 
by others for epitope mapping and that such longer fragments may well be 
able to bind to more class II MHC molecules than shorter versions of the same 
HEL regions. Consistent with this assumption, synthetic versions of selected 
cathepsin D-released HEL fragments 1-31, 32-62, 63-83 and 109-129, which 
range from 21 to 31 amino acids in length, displayed a much higher degree of 
promiscuity than previously examined shorter peptides.12 Comparing the 
sequences of previously reported epitopes12 агЛ rcference"therem with those of the 
peptides used in table 2 illustrates that the more promiscuous behaviour of the 
longer peptides is difficult to explain by assuming thatlonger peptides simply 
contain additional epitopes in their sequence for different class II MHC 
molecules. Extensive studies by many groups on the location of HEL epitopes 
do not provide data to indicate the presence of such additional epitopes in the 
sequence tested here. Rather, simple extension of the sequence by itself 
appears to contribute to the observed promiscuity. It should be noted that at 
least a fraction of the peptides tested are likely to be processed further by 
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either intracellular or extracellular proteases during the proliferation assay. 
Hence, the sequences eventually presented to T-cells may not be identical to 
the sequences initially added. However, also continued processing cannot 
provide an explanation for the observed promiscuity. 
Although it is not immediately apparent exactly how length affects 
promiscuity, our observations are in line with previous reports on the MHC 
binding properties of fragments of lysozyme as well as from other model 
proteins.2431 These studies illustrate that even small alterations in peptide 
structure and/or length may have significant effects upon the ability of a 
peptide to bind to different class II MHC molecules. 
Our data hold a caveat to epitope mapping by exclusively employing relatively 
short peptides (10- to 20-mers) indicating that such a strategy may 
underestimate the potential promiscuity of naturally processed antigen 
fragments for different class II MHC molecules. In addition, our findings 
suggest that synthetic peptides for vaccination or immunotherapy may perhaps 
be rendered more widely applicable in an outbred population by simply 
increasing peptide length. 
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CHAPTER 5 
SUPPRESSION OF HEN EGG LYSOZYME-INDUCED ARTHRITIS BY 
INTRAVENOUS ANTIGEN ADMINISTRATION: NO ROLE IN THIS 
FOR ANTIGEN-DRIVEN BYSTANDER SUPPRESSION 
Marike J.M. Jacobs, Astrid E.M. van den Hoek, Levinus B.A. van de Putte 
& Wim В. van den Berg 
Clinical and Experimental Immunology 96: 36-42; 1994 
SUMMARY 
The induction of tolerance, particularly by intervention before established 
immunity, is widely accepted. We studied the effects of intravenous (i.v.) 
administration of hen egg lysozyme (HEL), before as well as after 
immunisation, on a HEL-induced arthritis. Arthritis and also cartilage 
destruction were almost completely suppressed when 100 μg HEL was injected 
before immunisation. Antigen-specific proliferative T-cell responses and IL-2 
production in vitro were inhibited. Antigen-specific Ig- and IgG,-titres were 
equal in control and tolerised mice, in contrast to lowered IgG^-titres in 
tolerised animals. Detailed histological studies showed that the immune 
complex-dependent polymorphonuclear cell phase (<24 h after arthritis 
induction) was equal for control and HEL injected mice. Only in the T-cell 
dependent phase of the arthritis (>24 h), did suppression become pronounced 
in tolerised mice. I.v. administration of 100 μg HEL after immunisation could 
only marginal reduce infiltrate and exudate, and no reduction of cartilage 
destruction was seen. An elegant way to interfere in an established immunity 
can be offered by creation of bystander suppression. We show that i.v. 
administration of HEL followed by triggering with HEL, at the moment either 
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of immunisation or arthritis induction, does not reduce a methylated BSA-
arthritis. We conclude that arthritis can be suppressed almost totally when 
HEL is injected i.v. before immunisation. Treatment after immunisation is less 
effective. The i.v. induced suppression is T-cell mediated and antigen-specific: 
no bystander suppression circuit can be generated. 
INTRODUCTION 
Induction of peripheral T-cell tolerance can be achieved by administering 
putative antigens before immunisation. Different ways of administration have 
been shown to be effective, e.g. oral feeding16, intraperitoneal (i.p.)7·8 and 
intravenous injection (i.v.).9"12 Most reported data describe intervention before 
immunisation. Few reports show successful interference in an already 
established immunity or disease.1·1314 An experimental autoimmune 
encephalomyelitis was totally prevented by a 3 times feeding of Myelin Basic 
Protein (MBP) before immunisation, whereas a partial suppression was seen 
when MBP was administered after immunisation.13 Peng et al. and Lamont et 
al. both showed that a large oral dose of antigen after immunisation was 
effective in suppressing Delayed Type of Hypersensitivity (DTH) responses. 
Suppression became less pronounced as the time interval between 
immunisation and feeding increased.114 Recently, oral administration of type II 
collagen was also found to be beneficial in Rheumatoid Arthritis patients.15 
The way suppression is created does not necessarily have to be antigen-
specific. Tolerance in an experimental autoimmune encephalomyelitis was 
achieved by feeding an irrelevant protein antigen. This way of suppression, 
mediated by a soluble factor, is termed 'antigen-driven bystander suppression'. 
The secretion and action of these soluble factors must occur in the local 
environment of the lymphoid tissue where the immune response is generated 
and/or at the inflamed site in the target organ.1617 Bystander suppression can 
be useful to interfere in an established immunity. By creating an additive 
immunity against an irrelevant harmless protein, one can induce bystander 
suppression, tending to influence the disease in question. Moreover, new 
prospects are offered in diseases where involved antigens are not known, such 
as Rheumatoid Arthritis. 
The aim of this study was, first, to try to prevent arthritis in an antigen-
specific way by i.v. administration of hen egg lysozyme (HEL) before 
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immunisation as well as after immunisation. Second, to test feasibility of 
bystander suppression in i.v. induced tolerance (never tested in i.v.-induced 
tolerance). Results show a nearly complete suppression of arthritis when 
antigen was administered before immunisation. Administration of HEL after 
immunisation could only induce a marginal suppression. I.v. administration of 
an irrelevant protein, in order to induce antigen-driven bystander suppression, 
could not induce any suppression. Different protocols of triggering suppressive 
cells (induced by i.v. administration) were tested, but unfortunately arthritis 
could not be modulated. We conclude that i.v.-induced tolerance is antigen-
specific. No antigen-driven bystander suppression can be created after i.v. 
administration of antigen, to modulate an antigen-induced arthritis. 
MATERIALS AND METHODS 
Materials 
Female C57B1/6 mice, aged 12-15 weeks, were bred in the Central Animal 
Laboratory. Methylated bovine serum albumin (grade V)(mBSA), BSA 
(fraction V), chicken egg albumin (grade III)(OVA), hen egg lysozyme (grade 
I)(HEL), casein (from bovine milk), l-ethyl-3(3-dimethyl-aminopropyl) 
carbodiimine hydroxychloride (EDC), and poly-L-lysine (PLL)(56 kD) were 
obtained from Sigma (St. Louis, MO, USA). To raise MW, HEL was coupled 
to PLL using EDC as activator. Coupled PLL was separated from free HEL 
by Sephadex G75 gel filtration. The ratio HEL/PLL in coupled product was 
found tobe l.1" 
Immunisation 
Mice were immunised in the fore footpads and subcutaneously (s.c.) in the 
flanks with 200 μg antigen emulsified in Complete Freund's Adjuvant 
(CFA)(Difco, Detroit, MI, USA). Additionally, 2x10' heat-killed Bordetella 
pertussis organisms (National Institute of Public Health, Bilthoven, the 
Netherlands) were administered i.p.. Seven days later booster injections were 
given s.c. (150 μg antigen/CFA). 
A milder immunisation protocol was used in order to induce antigen-driven 
bystander suppression. Mice were immunised in the forepaws with 100 ^g 
mBSA/CFA or HEL/CFA, 7 days after i.v. injection of respectively 100 μg 
HEL or BSA. No booster injections were given. 
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Induction of tolerance 
Mice were injected i.v. in the tail vein with 25, 100 or 500 μg HEL, BSA, or 
casein dissolved in 0.2 ml PBS or PBS alone. Antigen was administered 7 
days before or 10 days after immunisation. 
Induction of bystander suppression 
A suppressive circuit was generated by i.v. injection of 100 μg HEL 7 days 
before mBSA-immunisation. Seven days after the first immunisation, booster 
injections were given. Regulatory cells were triggered in 3 ways: (1) s.c. 
injection of 250 ^g HEL 8 hours after the first immunisation, (2) s.c. injection 
of 250 μg HEL 2 days before arthritis induction, (3) i.a. injection of 50 μg 
HEL at the moment of arthritis induction (figure la). 
In the mild immunisation protocol (as described earlier), regulatory cells were 
created by i.v. injection of 100 μg HEL. These cells were triggered 8 hours 
after immunisation in the same forepaws by s.c. injection of 250 μg HEL 
(figure lb). 
These protocols were performed identically with BSA as tolerising protein in 
HEL-immune mice. 
Antibody determination 
Antibodies (Ab) were determined in sera of individual mice with an Enzyme 
linked immunosorbent assay (ELISA). Polystyrene microtitre plates (Costar, 
Cambridge, MA, USA) were coated overnight at room temperature with 150 
μΐ HEL (100 μg/ml PBS) per well. The plates were washed three times with 
0.05% Tween-20 in PBS, and coated with 150 μΐ 1% gelatin dissolved in PBS 
(1 h, room temperature) to avoid non-specific binding. After washing, plates 
were incubated with two-fold dilutions of the sera (in 0.5% gelatin in PBS, 2 
h, 37 °C). The plates were washed three times and incubated (1 h, 37°C) 
respectively with 1:500 diluted goat anti-mouse total Ig-, IgG,-, IgG^-, IgG2b-, 
IgE-, and IgM-PO (Nordic, Tilburg, the Netherlands). After washing five 
times, substrate (10 ml 50 mM NaPi, 8 mg 5-aminosalicylacic, and 8 μΙ 30% 
H202) was added, and after 20 min extinction was measured at 450 nm. Ab-
titre was expressed as the dilution at a half maximum extinction. 
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(1) 250 μ
Β 
HEL s.c. 
8 h 
(2) 250 μ 6 
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day 19 
(3) 50 μ% 
HEL i.a 
day 21 
day -7 day 0 day 7 day 21 
100 ¿tg immun. booster 
HEL ì.v. mBSA/CFA (s.c.) 
(s.c. +forepaws) 
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8h 
day 0 
immun. 
mBSA/CFA 
(forepaws) 
day 14 
l.a. 60 μg 
mBSA 
Figure 1. Protocols used to induce bystander suppression. Bystander 
suppression was induced in a standard immunisation protocol (a), and in a 
mild immunisation protocol (b). Both protocols were performed identically with 
BSA as tolerising protein in HEL-immune mice. 
Arthritis induction and measurement 
Mice were injected intra-articularly (i.a.) in the right knee joint with 30 /¿g 
PLL.HEL or 60 ^g mBSA in 6 μ\ PBS, 21 days after the first immunisation. 
In case of the milder immunisation protocol, arthritis was induced 14 days 
after immunisation. Joint inflammation was determined 3 and 7 days after 
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arthritis induction by measurement of "mTc pertechnetate uptake of the knee 
joint. Mice were sedated with chloral hydrate (i.p.) and injected s.c. in the 
neck region with 10 μΟϊ T c . After 20 min, radioactivity was assessed by 
measuring both knees in a fixed position. Joint swelling was expressed as the 
ratio of the Tc-uptake in the left and right knee joints (L/R ratio).19 
Histology 
Groups of at least 6 mice were killed 6, 12, 24, 48, 72 hours, or 7 days after 
arthritis induction. Knee joints were dissected and processed for histology, as 
described previously.20 Whole knee joint sections (6 μιτι) were prepared and 
stained with haematoxylin/eosin or saffranin O. Arthritis was scored 
semiquantitatively double blind in a standardised frontal section of the knee 
joint which included menisci, cruciate ligaments and patella. Extent of cellular 
infiltration of synovial tissue, cellular exudate in the joint space, and cartilage 
destruction were graded on a scale ranging from 0 (no cells or matrix 
depletion) to 3. 
T-cell proliferation and IL-2 detection 
T-cells were examined for antigen-specificity by a 3[H]thymidine incorporation 
assay. Seven days after arthritis induction, mice were sacrificed and draining 
LN were removed aseptically. A single cell suspension was made by gentle 
teasing in a sterile infusion system (NBPI BV, Emmer-Compascuum, the 
Netherlands). Cells were washed once and enriched for T-lymphocytes by 
nylonwool adherence (30 min). Non adherent cells were collected and adjusted 
to a concentration of 2xl06/ml. As a source of antigen presenting cells (APC), 
naive spleen cells were used. Spleens were removed aseptically, a cell 
suspension was made, and erythrocytes were lysed with 0.16 M NH4C1 0.17 
M TRIS-HC1, pH 7.2 for 1 min at room temperature. Cells were washed three 
times and adjusted to a concentration of lxl07/ml. Proliferation medium 
consisted of RPMI-1640 Dutch modification (dm) completed with 20 mM 
glutamine, 10 mM pyruvate, 0.5 mM /3-mercaptoethanol and 2% homologous 
serum. Different antigen, and concanavalin A concentrations (con A) were 
made (100 μΐ) in 96-well round-bottom microtitre plates (Costar, Cambridge, 
MA). Additionally 50 μΙ APC (IxlO6) and 50 μΙ T-lymphocytes (1x10s) were 
added per well, and incubated for 72 hours. For determination of proliferative 
capacity, 1 μΟ\ 3[H]thymidine/weIl was administered. After 16 h cells were 
harvested with a cell harvester (LKB, Turku, Finland) and the amount of 
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3[H]thymidine incorporation was counted in a betaplate liquid scintillation 
counter (LKB). 
IL-2 production was also measured after 72 hours of incubation. Round 
bottom plates were centrifugated and 100 μΐ of the supernatent was tested in a 
CTLL-assay. CTLL-cells, highly specific for IL-2, were collected in active 
log-phase growth. Cells were washed three times, and 5ХІ03 cells (in 100 μΐ) 
were added to 100 μ\ supernatant. After 48 hours of incubation, 1 /xCi 
3[H]thymidine/well was added. 16 Hours later cells were harvested with a cell 
harvester and 3[H]thymidine incorporation was determined. 
Statistics 
Results are expressed as mean + standard deviation. Statistical significance 
was tested by using the Wilcoxon's Rank Sum test. Significance was reached 
when Ρ values were less then 0.05 (*). 
RESULTS 
Dose- and time-dependent down-regulation of arthritis 
Small amounts of HEL were administered i.v. in order to modulate a HEL-
induced arthritis. Three different doses of HEL (500, 100 and 25 μg) were 
injected in the tail vein 7 days before immunisation. Control mice received 
500 μg casein i.v.. Three and seven days after arthritis induction, joint 
swelling was measured. Results (figure 2) show a clear suppression of joint 
swelling by HEL-treatment before immunisation. A dose of 25 ^g was less 
effective than 500 and 100 μg. 
In addition, effects of HEL administration after immunisation were studied. 
Injection of high doses of HEL are difficult in case high systemic anti-HEL 
titres exist, since circulating immune complexes can cause a lethal shock. 
Therefore only 100 μg of HEL was administered 10 days after immunisation. 
Results (figure 2) show a significant drop in joint swelling at day 3, although 
not as effective as compared with treatment before immunisation. Histological 
findings parallel efficacy of treatment before immunisation; a significant dose-
dependent decline in the amount of infiltrating cells, exudate and loss of 
proteoglycans was seen on day 3 of the arthritis. 
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Figure 2. Effects of i. v. administration of HEL on joint swelling. Different 
doses of HEL (500, 100, or 25 ßg) were injected 7 days before HEL-
immunisation, or 100 μg was injected 10 days after immunisation. Control 
mice recieved 500 μg casein. Joint swelling was measured on days 3 (black 
bars) and 7 (hatched bars), and are expressed as the mean (± sd) of L/R-
ratios of 8 mice per group (* p< 0.05). 
Intervention after immunisation showed no histological improvement compared 
to controls (figure 3a). In the later phase (day 7) of the control arthritis, 
infiltrate and cartilage depletion were still marked, while exudate faded away. 
All treated groups showed a reduced amount of infiltrate in this stage of the 
disease, but reduced cartilage depletion was only seen in mice treated before 
immunisation. Of interest, marked recovery of the depleted matrix was noted 
in the tolerised mice at day 7, whereas persistent proteoglycan depletion was 
noted in the control (figure 3b). 
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Figure 3. Effects of i. v. administration of HEL on infiltrate (black bars), 
exudate (hatched bars) and cartilage depletion (open bars). Different doses of 
HEL were injected 7 days before or 10 days (dlO) after immunisation. 
Controls recieved 500 μ# casein. Histology was scored on day 3 (a) and day 7 
(b) on a scale ranging from 0 to 3. Data are expressed as the mean (± sd) of 
8 mice per group (* p< 0.05). 
Histological development of arthritis in controls compared with tolerised mice 
To gain more insight in the mechanism of suppression, a detailed histological 
study of sequential alterations was carried out. Tolerance was induced by 
administration of 100 μg HEL 7 days before immunisation. Histology was 
taken 6, 12, 24, 48 and 72 hours after arthritis induction. Control mice 
developed a moderate arthritis, histologically characterised by predominantly 
polymorfonuclear cells in the joint space (exudate), followed by infiltrate in 
the synovial and surrounding tissues. Later on the proportion of mononuclear 
cells increases. Figures 4a, and 4b illustrate that the amount of exudate peaked 
at 24 hours, while the infiltrate developed more slowly. Maximum loss of 
proteoglycans was already reached after 24-48 hours. In tolerised mice, no 
significant histological improvement was seen after 6, 12 and 24 hours. This 
early stage of the disease is characterised by polymorfonuclear cells which 
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enter the joint as a result of local immune complexe formation. In the later T-
cell specific phase, the proportion of mononuclear cells increases.21 In this 
phase (> 24 h), exudate and infiltrate in particular, were significantly lowered 
in the treated group. Differences became even more pronounced after 72 
hours. At this moment loss of proteoglycans was diminished in the tolerant 
group, indicating reversibility of cartilage depletion (figure 4c). 
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Figure 4. Sequential alterations in histology of HEL-induced tolerance (100 
μg HEL i.V., day -7; represented by striped bars). Control mice recieved 100 
μg BSA (represented by black bars). Histology was scored on 6, 12, 24, 48, 
and 72 hours after arthritis induction on a scale ranging from 0 to 3. Data of 
infiltrate (a), exudate φ), and cartilage depletion (c) are expressed as the 
mean (± sd) of 7 mice per group (* p< 0.05). 
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Effects of tolerance induction on proliferative responses and antibody titres 
Proliferation assays were performed with draining LNC (forepaws). Table 1 
shows proliferative responses and IL-2 production on antigen and con A. 
Antigen-specific proliferation as well as IL-2 production were clearly 
abrogated in tolerant mice, while con Α-responses were equal to control mice. 
These results are indicative for suppression of the Thl population. 
Table 1. Effects of i.v.administration of 100 μg HEL on antigen-specific 
proliferative capacity and IL-2 production of LNC. 
Antigen concentration 
(/ig/ml) 
medium (cpm) 
HEL 5 
HEL 25 
HEL 100 
HEL 250 
con A 2.5 
Proliferation 
control HEL 
61 64 
24 5 
68 19 
98 34 
154 35 
4667 3108 
IL-2 prod 
control 
52 
29 
53 
64 
81 
1011 
uction 
HEL 
48 
5 
14 
18 
25 
1307 
Footnote: HEL was injected 7 days before immunisation. Control mice 
received 100 μg BSA. Results are expressed as stimulation indices (SI); 
medium values are expressed as counts per minute (cpm). 
To investigate this also at the antibody level, sera were collected. Total Ig and 
different subclasses were determined, to gain an impression of activation state 
of ТЫ- and Th2-cells. Table 2 shows dilutions of sera, where 50% of the 
maximal extinction is reached. 
IgM, IgE and IgG
:b-titres were very low in all groups. IgG^-titres were dose-
dependently suppressed in groups treated before immunisation, while total Ig-
and IgG,-titres were equal in all groups. Overall, differences in Ab-titres were 
small, and significant amounts of immune complexes will still be formed in 
the tolerised mice. This is reflected in histological findings, where no decrease 
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in cell influx was seen in the early phase (<24 hr). Later on, in the T-cell 
dependent stage of the disease, suppression of cell influx became pronounced 
in tolerised mice. 
Table 2. Effects of i.v. administration of 100 μg HEL on antigen-specific 
Ab-titres in sera. 
casein (control) 
500 /tg HEL 
100 Mg HEL 
25 μg HEL 
100 μg HEL (day + 10) 
total Ig 
1280 
640 
1280 
1280 
1360 
Dilution 
IgG, 
640 
530 
640 
640 
640 
IgG2
a 
420 
80 
290 
340 
420 
Footnote: Different doses of HEL were injected 7 days before or 10 days (100 
μg, day 10) after immunisation. Ab-titres are expressed as the dilution where 
half maximal extinction is reached (mean of 7 different mice per group). 
Standard deviations never exceed one dilution step. 
Feasibility of antigen-driven bystander suppression in i.v. induced tolerance 
Feasibility of antigen-driven bystander suppression was tested in case tolerance 
was induced by i.v. administration of HEL. Seven days after tolerising, mice 
were immunised and boosted with the non-related antigen mBSA/CFA. 
Arthritis was induced at day 21 by i.a. injection of mBSA. Miller et al.16 
stated that the secretion and action of antigen-nonspecific factors by regulatory 
cells (induced by oral feeding) had to occur in the local environment of the 
lymphoid tissue where the immune response was created and/or at the 
inflamed site in the target organ. Therefore triggering of regulatory cells 
(created by i.v. injection of HEL) was performed using 3 different protocols 
(as illustrated in figure la): 8 hours after the first immunisation (s.c), 2 days 
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before arthritis induction (s.с), or at the time arthritis was induced (i.a.). 
Table 3 shows results of these experiments: totally no suppression of arthritis 
was achieved. 
Table 3. Feasibility of antigen-driven bystander suppression in a mBSA-
induced arthritis. 
i.v. 
PBS 
casein 
HEL 
PBS 
HEL 
PBS 
HEL 
Trigger / location / 
time after immunisation 
250
 Mg HEL/ s.с/ 8 h 
250 μg HEL/ s.с/ 8 h 
250 Mg HEL/ s.с/ 8 h 
250 μg HEL/s.c./day 19 
250 μg HEL/s.c./day 19 
50 Mg HEL/i.a./day 21 
50 Mg HEL/i.a./day 21 
Joint swelling (L/R ratio) 
day 3 
2.22 ± 0.27 
2.42 ± 0.37 
2.63 ± 0.21 
2.07 ± 0.27 
2.03 ± 0.42 
2.04 ± 0.35 
2.07 ± 0.24 
day 7 
1.92 ± 0.18 
2.00 ± 0.40 
2.05 ± 0.13 
1.35 ± 0.13 
1.47 ± 0.13 
1.46 ± 0.10 
1.34 ± 0.11 
Footnote: Feasibility of antigen-driven bystander suppression by i. v. injection 
of HEL (100 μg, day -7) in a mBSA-induced arthritis. Three representative 
experiments show different ways of triggering regulatory cells. Joint swelling 
was measured on days 3 and 7, and are expressed as the mean (± sd) ofL/R-
ratios of 7 mice per group. 
In order to interfere more successfully in immunity, a milder immunisation 
protocol was used, consisting of one mBSA-immunisation in the forepaws. 
Eight hours later, the s.c. trigger with HEL was given in the same forepaws 
(illustrated in figure lb). Two weeks after immunisation, arthritis was 
induced. A moderate arthritis developed in controls, but also in treated mice 
(data not shown). 
Earlier findings have demonstrated that successful tolerance induction may 
depend on the type of the antigen involved. Modulation of a mBSA-immunity 
by oral administration of mBSA appeared to be difficult.6 Therefore above 
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mentioned experiments were repeated in HEL-immunised mice, with 
generation of regulatory cells by injecting BSA before immunisation. Again, 
no suppression of arthritis was seen (data not shown). Out of these 
experiments one may conclude that priming for antigen-driven bystander 
suppression does not occur by i.v. injection of protein antigens. 
DISCUSSION 
In the present report we have studied the effects of i.v. administration of 
antigen on an experimental model of arthritis. Compared to oral feeding, only 
small amounts of protein are needed to induce suppression. Suppression of 
DTH can be achieved by administering a particular antigen before 
immunisation.2·4-6·7·911 Our results show that i.v. injection of HEL before HEL-
immunisation can almost totally prevent arthritis. This suppression is dose 
dependent, although as little as 25 μg HEL is still sufficient to down-modulate 
an arthritis significantly. Joint swelling, infiltrate and exudate were drastically 
reduced. Cartilage depletion was reduced in the acute phase of the arthritis, 
but still marked. In the chronic stage of the disease, cartilage depletion showed 
up to be reversible in tolerised mice (figures 3a,b). Additional kinetic studies 
demonstrated that, up to 24 hours after arthritis induction, all histological 
parameters developed equal in controls and tolerised animals. This phase of 
the arthritis depends predominantly on the formation of immune complexes. 
Determination of Ab-titres has shown that only IgG^-titres were impaired in 
tolerised mice; total Ig-titres remained unchanged (table 2). These findings 
correspond with histological findings in the Ab-dependent phase of the 
arthritis. Others have also shown that the early phase is characterised by 
predominantly polymorphonuclear cells, whereas later on the proportion of 
mononuclear cells increases.21 In the T-cell dependent stage of the arthritis 
(>24 h) suppression becomes significant compared to controls. We conclude 
that interference before immunisation is very effective in preventing joint 
disease and cartilage destruction. 
The mechanism that is at the root of i.v.-induced tolerance remains unclear. 
Suppression can be achieved by several mechanisms, including active 
suppression by CD8+ T-lymphocytes22"24, anergy of antigen-specific T-
lymphocytes25'27, or suppression by Th2-cells.28·29 Proliferation assays, 
performed with draining LNC of tolerised mice, showed an antigen-specific 
suppression of proliferative capacity and IL-2 production. This indicates 
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suppression of Thl-cells. Thl-cells mainly produce IL-2 and IFNY, while 
Th2-cells are producers of IL-4, IL-5 and IL-10. IL-4 and IL-10, known as 
immunosuppressive cytokines, act inhibitory on Thl-cells (directly and/or via 
macrophages). Besides, monocytes and as a result IL-1, IL-6 and TNF-
production, can be inhibited. IL-4 may also influence the antigen-specific Ab-
repertoire; the shift from IgE, IgM and IgGt to IgG^, IgG^ and IgG3 is 
inhibited.25,2830. To gain an impression of activation state of Th2-cells, 
different subclasses of antigen-specific Ab-titres were determined. Only IgG^-
titres were reduced, while total Ig- and IgG,-titres remained equal to controls. 
IgE- and IgG;b-titres were very low in both groups. The Ab-data point to an 
activation of Th2-cells, but preliminary data of anti-IL-4 experiments can not 
confirm this. Our data indicate that the mechanism of i.v. induced tolerance 
might be due to anergy of antigen-specific T-lymphocytes (manuscript in 
preparation). 
Although i.v. tolerance induction before immunisation is widely accepted, the 
modulation of an established immunity remains more difficult. Only a few 
studies report positive effects of tolerance induction after immunisation.I,n·14 
Our results show some beneficial effects on joint swelling after late i.v. 
injection. Also the infiltrate in the chronic stage of the disease was 
significantly less, but cartilage destruction was still severe and equal to 
controls. I.v. injection of an antigen after immunisation may cause problems in 
immune mice. If high titres of antigen-specific Ab exist, immune complexes 
will be formed, presumably resulting in shock and death. Therefore only low 
dose tolerance, probably less effective than high dose, could be studied. The 
last mentioned problem, and the marginal suppression obtained by late 
interference, prompted us to look for other possible ways of tolerance 
induction. Antigen-driven bystander suppression was found as mechanism for 
orally induced tolerance.16. Bystander suppression is mediated by a soluble 
factor (TGFjS), which is produced after oral feeding of OVA in an EAE.31. 
This non-specific form of suppression offers possibilities in diseases where the 
antigen involved is unknown, like Rheumatoid Arthritis. Besides, by creating 
an additive immunity against a harmless irrelevant protein, an already 
established immunity (or disease) can be influenced. Feasibility for i.v.-
induced tolerance was studied in our model for arthritis. The most obvious 
approach was chosen, namely intervention before immunisation. Results show 
that HEL-induced regulatory cells (obtained by i.v. injection of HEL) were not 
capable of down-regulating an mBSA-arthritis. Different triggering protocols 
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were tested, because the action of antigen-nonspecific factors by regulatory 
cells must occur in the local environment of the lymphoid tissue where the 
immune response is generated, and/or at the inflamed site in the target organ 
where the antigen is present.16. However, our experiments show that triggering 
with HEL in the environment of immunisation (s.c. in the flanks or forepaws), 
or simultaneously with arthritis induction in the joint, did not have any effects 
on the severity of arthritis. Even when milder immunisation protocols were 
used, no improvement of arthritis was seen. Previous work from others and 
ourselves have shown that success of tolerance induction may depend on the 
type of antigen involved. Suppression of a mBSA-immunity showed up to be 
difficult by feeding mBSA.6·3234. Therefore effects of i.v. injection of BSA 
were studied on a HEL-induced arthritis. Although suppressive signals are 
described for oral and s.c.-induced tolerance16,22, we were not able to exert 
any influence of i.v. administration on an antigen-induced arthritis. 
In conclusion, arthritis can be suppressed when i.v.-treatment is antigen-
specific. This suppression is T-cell mediated, probably acting via anergy of 
antigen-specific Τ lymphocytes. 
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CHAPTER 6 
ANERGY OF ANTIGEN-SPECIFIC T-LYMPHOCYTES IS A POTENT 
MECHANISM OF INTRAVENOUSLY INDUCED TOLERANCE 
Marike J.M. Jacobs, Astrid E.M. van den Hoek, Levinus B.A. van de Putte 
& Wim В. van den Berg 
Immunology 82: 294-300; 1994 
SUMMARY 
Intravenous (i.v.) injection of an antigen before immunisation has been shown 
to be a potent way to induce suppression at the T-cell level. In this study we 
demonstrate an almost complete suppression of arthritis (using antigen induced 
arthritis as a model) by i.v. injection of 100 μg hen egg lysozyme (HEL) 7 
days before immunisation. Underlying mechanisms, including suppression by 
CD8+ T-lymphocytes, suppression by Т
Ы р е г 2 (Th2) lymphocytes, or anergy of 
antigen-specific T-lymphocytes, were studied. In vivo treatment with either 
anti-CD8 or anti-IL-4 could not abrogate i.v. induced tolerance. Lymphocyte 
stimulation assays show reduced antigen-specific proliferative responses and 
IL-2 production in tolerised mice. The possible role of soluble suppressive 
cytokines were examined in vitro by adding anti-IL-4, anti-IL-10 or anti-
TGFjS. Neutralisation of these factors could not diminish suppression. Finally, 
anergy of antigen-specific T-lymphocytes was tested as possible mechanism for 
i.v. induced tolerance. Results demonstrate that reduced proliferative T-cell 
responses are reversible: incubation of tolerised lymph node cells for 5 days in 
addition of rIL-2, fully restored proliferative capacity back to normal. We 
therefore conclude that the main mechanism of i.v. induced tolerance in our 
model is anergy of antigen-specific T-lymphocytes. 
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INTRODUCTION 
A potent way to induce antigen-specific peripheral T-cell tolerance is i.v. 
administration of the particular antigen before immunisation.1"3 Mechanisms 
involved may be several, including antigen-specific active suppression by 
CD8+ T-lymphocytes5"8, suppression by Th2-lymphocytes and production of 
soluble factors (IL-4, IL-10, TGF/3)9"16, or anergy of antigen-specific T-
lymphocytes.11·17,18 For a long time, active suppression by antigen-specific 
CD8+ T-suppressor cells has been supposed to be the only mechanism of 
suppression. However, several observations could not be explained on the 
basis of this mechanism. More recently the potential role of suppressive CD4+ 
T-lymphocytes was demonstrated.9·111317"21 Cytokines produced by Thl and 
Th2-subsets were shown to be potent immunomodulators. Thl-cells, producers 
of IL-2 and IFNY, can be antagonised by Th2-cell cytokines. IL-4 can act 
directly on Thl-cells, while IL-10 most likely inhibits the function of 
macrophages as APC.10,22,23 Both cytokines can inhibit monocytes in their 
production of inflammatory cytokines e.g. IL-1, IL-6, and TNFa. IL-4 also 
has an influence on the antigen-specific Ab repertoire: the shift from IgE, IgG! 
and IgM to IgG^, IgG2b and IgG3 is inhibited. In high dose parenteral 
tolerance, unresponsiveness of Thl- but not Th2-cells was demonstrated12, 
resulting in inhibition of T-cell proliferation, and of IL-2- and ΙΡΝγ-
production, whereas IL-4 secretion was not affected (IL-4 mediated immune 
regulation). Another possible mechanism responsible for T-cell tolerance is 
anergy of T-lymphocytes; oral administration of high doses of antigen has 
been shown to result in a diminished IL-2 production and IL-2 receptor 
expression. This state of anergy could be reversed in vitro by rIL-2 
stimulation.17,24 
More than one of the mechanisms described may play a role in tolerance 
induction at the same time. This may depend on the way the antigen is 
administered and/or the type or chemical structure of the antigen involved.3·25" 
27
 In a number of studies the mechanism of tolerance has been investigated 
after oral feeding and intraperitoneal (i.p.) administration, but less is known 
about i.v.-induced tolerance. Main question of the present study was: what 
kind of mechanism(s) is (are) involved in i.v.-induced suppression of 
inflammation using antigen induced arthritis as a model ? To answer this 
question, previously mentioned mechanisms were successively examined. 
Results show an antigen-specific suppression of arthritis by iv administration 
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of hen egg lysozyme (HEL) before immunisation. CD8" T-lymphocytes were 
not responsible for the tolerance seen. Also neutralisation of the soluble factors 
IL-4, IL-10 and TGF/3, produced by Th2-cells, could not abrogate tolerance. 
In vitro studies indicated that reduced antigen-specific proliferative responses 
could be reversed by rIL-2 stimulation. From these data it seems most likely 
that i.v.-induced tolerance results from anergy of antigen-specie T-
lymphocytes. 
MATERIALS AND METHODS 
Materials 
Female C57B1/6 mice, aged 12-14 weeks, were bred in the Central Animal 
Laboratory. BS A (fraction V), hen egg lysozyme (grade I)(HEL), l-ethyl-3(3-
dimefhyl-aminopropyl) carbodiimine hydroxychloride (EDC), poly-L-lysine 
(56 kD)(PLL), and rat-IgG were obtained from Sigma (St. Louis, MO, USA). 
To raise MW, HEL was coupled to PLL using EDC as activator. Coupled 
PLL was separated from free HEL by Sephadex G75 gel filtration. The ratio 
HEL/PLL in coupled product was found to be 1,28 Monoclonal Ab produced 
by S4B6- (anti-IL-2). 1 IBI 1- (anti-IL-4), and 2.43 (anti-CD8)-hybridomas 
(obtained from American Type Culture Collection, Rockville, MD) were 
purified by HPLC-technique, using a protein G-column. Murine recombinant 
IL-2, and monoclonal ratamouse IL-10 were obtained from Genzyme (Boston, 
MA). Monoclonal mouse-anti-mouse TGF/3 was kindly provided by Dr. 
Moore (Gentech. Inc., San Fransisco).29 
Immunisation and induction of tolerance 
Mice were immunised in the footpads of the forelegs and subcutaneously (sc) 
in the flanks with 200 μg antigen emulsified in Complete Freund's Adjuvant 
(CFA)(Difco, Detroit, MI, USA). Additionally, 2x10" heat-killed Bordetella 
pertussis organisms (National Institute of Public Health, Bilthoven, the 
Netherlands) were administered intraperitoneal I y (i.p.). Seven days later 
booster injections were given s.c. (150 μg antigen/CFA). 
To obtain tolerance, mice were injected i.v. in the tail vein with 100 μg HEL 
7 days before immunisation. Control mice received 100 μg BSA dissolved in 
0.2 ml PBS or PBS alone. 
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Arthritis induction and assessment 
Mice were injected intra-articularly (i.a.) in the right knee joint with 30 μg 
PLL.HEL in 6 μΐ PBS, 21 days after the first immunisation. Joint 
inflammation was determined 3 and 7 days after arthritis induction by 
measurement of " T c pertechnetate uptake of the knee joint. Mice were 
sedated with chloral hydrate (i.p.) and injected sc in the neck region with 10 
дСі T c . After 20 min, radioactivity was assessed by measuring both knees 
in a fixed position. Joint swelling was expressed as the ratio of the " r e ­
uptake in the left and right knee joints (L/R- ratio).30 
Histology 
Groups of at least 6 mice were killed 3 or 7 days after arthritis induction. 
Knee joints were dissected and processed for histology, as described 
previously.31 Whole knee joint sections (6 μίτι) were prepared and stained with 
haematoxylin/eosin or saffranin O. Arthritis was scored semiquantitative!y 
double blind in a standardised frontal section of the knee joint which included 
menisci, cruciate ligaments and patella. Extent of cellular infiltration of 
synovial tissue, cellular exudate in the joint space, and cartilage destruction 
were graded on a scale ranging from 0 (no cells or matrix depletion) to 3 
(dense cell infiltrate and/or exudate, total loss of saffranin О staining). 
Antibody determination 
Ab were determined in sera of individual mice with an ELISA. Polystyrene 
microtitre plates (Costar, Cambridge, MA, USA) were coated overnight at 
room temperature with 150 μΐ HEL (100 μg/ml PBS) per well. The plates 
were washed three times with 0.05% Tween-20 in PBS, and coated with 150 
μΐ 1% gelatin dissolved in PBS (1 h, room temperature) to avoid non-specific 
binding. After washing, plates were incubated with two-fold dilutions of the 
sera (in 0.5% gelatin in PBS, 2 h, 37 °C). The plates were washed three times 
and incubated (1 h, 37°C) respectively with 1:500 diluted goat anti-mouse total 
Ig-, IgG,-, IgG*-, IgG
a
-, IgGj, IgE-, and IgM-PO (Nordic, Tilburg, The 
Netherlands). After washing five times, substrate (10 ml 50 mM NaPi, 8 mg 
5-aminosalicylacic, and 8 μ\ 30% H202) was added, and after 20 min 
extinction was measured at 450 nm. Ab-titres were expressed as the dilution at 
a half maximum extinction. 
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Proliferation, IL-2 and IL-4 detection 
T-cells were examined for antigen-specificity by a ^Hjthymidine incorporation 
assay. Seven days after arthritis induction, mice were sacrificed and draining 
lymph nodes (forepaws) were removed aseptically. A single cell suspension 
was made by gentle teasing in a sterile infusion system (NBPI BV, Emmer-
Compascuum, the Netherlands). Cells were washed once and enriched for T-
lymphocytes by nylonwool adherence (30 min). Non adherent cells were 
collected and adjusted to a concentration of 2xl06/ml. As a source of antigen 
presenting cells (APC), naive spleen cells were used. Spleens were removed 
aseptically, a cell suspension was made, and erythrocytes were lysed with 0.16 
M NH4C1 0.17 M TRIS-HCI, pH 7.2 for 1 min at room temperature. Cells 
were washed three times and adjusted to a concentration of lxl07/ml. 
Proliferation medium consisted of RPMI-1640 dutch modification (dm) 
completed with 20 mM glutamine, 10 mM pyruvate, 0.5 mM ß-
mercaptoethanol and 2% homologous serum. Different Ag-, and concanavalin 
A (con A)-concentrations were made (100 μΐ) in 96-well round-bottom 
microtitre plates (Costar, Cambridge, MA). Additionally 50 μΙ APC (lxlO6) 
and 50 μΐ T-lymphocytes (lxlO5) were added per well, and incubated for 72 
hours. For determination of proliferative capacity, 1 μα 3[H]thymidine/well 
was administered. After 16 h cells were harvested with a cell harvester (LKB, 
Turku, Finland) and the amount of 3[H]thymidine incorporation was counted in 
a betaplate liquid scintillation counter (LKB). 
To measure IL-2, plates were incubated for 72 hours. IL-4 production was 
measured after 5 days. After incubation, round bottom plates were 
centrifugated and 100 μΐ of the supernatent was tested. IL-2 levels were 
determined using an IL-2 specific CTLL line. Cells were washed three times, 
and 5xl03 cells (in 100 μΙ) were added to 100 μΐ supernatant. For IL-4 
determination,the IL-4 dependent CT.4S line was used (kindly provided by 
WE Paul). Cells were washed and lxlO4 cells (in 100 μΐ) were added to 100 
μΐ supernatant. After 48 hours of incubation, 1 μΟϊ 3[H]thymidine/well was 
added. 16 Hours later CTLL and CT.4S cells were harvested with a cell 
harvester and 3[H]thymidine incorporation was determined. Specificity of IL-2 
and IL-4 signals was chequed by administration of S4B6 (anti-IL-2) and 1 IBI 1 
(anti-IL-4) m Ab. 
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Ab-treatment 
For anti-CD8+ mAb-treatments, animals were given 4 i.p. injections of 100 /xg 
HPLC-purified 2.43 in PBS on days 18, 19, 20, and 26. Control animals were 
given an equal amount of rat-IgG or PBS alone. This dose of 2.43 has been 
shown to deplete > 99% of CD81 T-lymphocytes.32" 
For anti-IL-4 mAb-treatments in vivo, mice were given i.p. injections of 
HPLC-purified l IBI l in PBS. Control animals received rat-IgG or PBS alone. 
Two different dosage schemes were employed: (a) 3 i.p. injections of l lB l l 
on days -8, -5, and -2; (b) 2 i.p. injections on days 20, and 23. 
For mAb-treatments in vitro, proliferation assays (as described earlier) were 
performed the presence of anti-IL-4 (25 ^g/ml), anti-IL-10 (25 Mg/ml), or 
anti-TGF/3 (100 μg/ml) during the total time of incubation. Controls consisted 
respectively of rat-IgG^, rat-IgM, or mouse-IgG. 
Reversal of T-lymphocyte anergy 
Nylon wool enriched lymph node cells (LNC)(draining on forepaws) from 
control and tolerised mice were incubated for 5 days in supplemented RPMI-
1640 dm containing 50 U rmIL-2/ml. Stimulated LNC were washed three 
times, and proliferation assays (as described earlier) were carried out just 
before and after rmIL-2 stimulation. 
Statistics 
Results are expressed as mean + standard deviation. Statistical significance 
was tested by using the Wilcoxon's Rank Sum test. Significance was reached 
when Ρ values were less then 0.05 (*). 
RESULTS 
Down-regulation of arthritis by i.v. administration 
The possibility of tolerance induction in an antigen induced arthritis (AIA) was 
studied by i.v. injection of 100 μg HEL 7 days before immunisation. After 
induction of a HEL-specific arthritis, joint swelling was measured. Tolerised 
mice showed a profound suppression of joint swelling compared to controls. 
Additional histology also demonstrated a significant decline in the amount of 
infiltrate, exudate and cartilage proteoglycan depletion (figure l). 
Anergy of T-lymphocytes 95 
score(day 3) 
3 00 
2 50 
2 00 
1 50 
1 00 
0 50 
(al 
- НШр 
шю& . 
ï 
score (day 7) 
(Ы 
* » 
_HÉi. 
control HEL control 
Figure I. Mice were injected i. v. with 100 μg HEL or BSA (control) 7 days 
before immunisation. Arthritis was induced, and on days 3 (a) and 7 (b) 
histology was taken. Infiltrate (black bars), exudate (hatched bars) and 
cartilage depletion (open bars) were scored on a scale ranging from 0 to 3. 
Data are expressed as the mean (± sd) of 8 mice per group. 
Further investigations were focussed on mechanisms responsible for i.v.-
induced tolerance. To this end lymphocyte stimulation tests of draining LNC 
were performed. Results in table 1 show a reduced antigen-specific 
proliferative response in tolerised mice, also reflected in a reduced IL-2 
production (detection level was 0.03 U/ml). In four out of five experiments, 
IL-4 production could not be detected in tolerant as well as in control mice 
(detection level was 0.1 U/ml). In one experiment IL-4 production was clearly 
measurable in control mice, but undetectable in tolerised mice (data shown in 
table 1). 
The latter findings suggest inactivation of Thl- and probably also of Th2-cells. 
The activation state of different Th subsets will be reflected in alterations of 
antigen-specific subclasses of Ab-titres. Previous data14 showed that IgG^-titres 
were reduced in tolerised mice (also demonstrated in table 4), while total Ig-
and IgG,-titres were equal in tolerised and control mice. IgM-, IgE-, IgG2b, 
and IgGj-titres were not detectable in both groups. These data suggest that the 
Th2-cell subset is activated by i.v. administration of HEL. 
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Table 1. Lymphocyte responses in control and tolerised mice. 
Proliferation3 IL-2b IL-4C 
Antigen cone. 
Oig/ml) control* HELe control HEL control HEL 
medium (cpm)r 
HEL 5 
HEL 25 
HEL 100 
HEL 250 
HEL 500 
con A 2.5 
con A 1.25 
83 
6 
27 
50 
50 
53 
2241 
1900 
80 
2 
8 
19 
21 
23 
2520 
1882 
45 
18 
49 
75 
43 
43 
629 
546 
43 
6 
15 
29 
13 
13 
1049 
1110 
140 
1 
2 
21 
57 
32 
26 
20 
131 
1 
1 
3 
1 
1 
15 
12 
a
 Antigen-specific proliferative responses of draining LNC were measured after 
3 days by 3H-thymidine incorporation (representative for 5 experiments). 
b
 IL-2 production in sups was measured after 3 days of incubation 
(representative of five experiments). 
c
 In four out of five experiments, IL-4 production could not be detected. In one 
experiment (data shown) clear responses could be measured. IL-4 
production in sups was measured after 5 days of incubation. 
d
 Control mice received 100 μ# BSA i. v. 7 days before immunisation. IL-2 
production in sups was measured after 3 days of incubation (representative 
for 5 experiments). 
' Mice were tolerised by i.v. injection of 100 μ-g HEL 7 days before 
immunisation. 
' Values of basal stimulations are in counts per minute (cpm), whereas all 
other results are expressed as stimulation indices. 
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Active suppression by CD8+ cells is not the mechanism responsible for i.v. 
suppression 
The role of CD8 + cells in tolerance induction was studied by administration of 
anti-CD8 Ab in vivo as well as in vitro. For in vivo studies, tolerant and 
control mice received anti-CD8 treatment on days 18, 19, 20 and 26. Control 
groups received rat-IgG or PBS. Efficacy of Ab-treatment was checked one 
day after the last Ab injection by FACS-analysis. The amount of CD8+ cells 
after Ab-treatment, as measured in spleen and draining LN, was less than 
1.5%. Data in table 2 show the amount of infiltrate and exudate 7 days after 
arthritis induction. 
Table 2. Effect of in vivo anti-CD8 treatment on abrogation of tolerance. 
Treatment" 
PBS / PBS 
PBS / rlgG 
PBS / anti-CD8 
HEL / PBS 
HEL / rlgG 
HEL / anti-CD8 
Infiltrateb 
1.4 ± 0.3 
1.3 ± 0.4 
1.3 ± 0.6 
0.1 ± 0.1 
0.1 ± 0.1 
0.1 ± 0.1 
Exudate0 
0.4 ± 0.2 
0.6 ± 0.2 
0.3 ± 0.3 
0.0 ± 0.1 
0 
0 
ь 
" Tolerised (100 μg HEL) and control mice (PBS) were treated 4 times with 
100 μ# anti-CD8, rat-IgG (rlgG), or PBS on days 18,19,20, and 26. 
Infiltrate and exudate were scored (scale 0-3) 7 days after arthritis induction. 
Data are expressed as the mean (± sd) of 10 mice per group. 
Administration of anti-CD8 in control mice (PBS i.v.) did not exert any 
influence on the severity of arthritis. As seen previously, the amount of 
infiltrate and exudate was reduced in HEL-treated mice. This suppression 
could not be abrogated by anti-CD8 treatment. 
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Is a shifi in Thl/Th2-cell balance responsible for i. v. induced tolerance ? 
Induction of the Th2-cell subset results in production of suppressive 
lymphokines, like IL-4 and IL-10.910 The role of IL-4 in i.v. tolerised mice 
was studied by anti-IL-4 treatment. In a first protocol anti-IL-4 was 
administered around the moment i.v. tolerance was induced (days -8, -5, -2). 
In a second set of experiments anti-IL-4 was administered around the time 
arthritis was induced (days 20, 23). Table 3 shows representative histological 
results of the two different anti-IL-4 treatments. 
Table 3. Effects of in vivo anti-IL-4 treatment on abrogation of tolerance. 
Treatment3 
PBS / PBS 
PBS / rIgG 
PBS / anti-IL-4 
HEL / rIgG 
HEL / anti-IL-4 
anti-IL-4 
-8, -5, 
infiltrateb 
1.3 ± 0.7 
1.3 ± 0.8 
1.3 ± 0.5 
0.2 ± 0.1 
0.1 ± 0.5 
on days 
and -2 
exudate*" 
0.4 ±0.3 
0.3 ± 0.1 
0.3 ± 0.1 
0 
0 
anti-IL-4 on days 
20 and 23 
infiltrateb 
1.8 ± 0.7 
2.0 ±0.4 
1.8 ± 0.8 
0.2 ± 0.1 
1.8 ± 0.8 
exudateb 
0.6 ±0.3 
0.5 ± 0.3 
0.3 ± 0.1 
0 
0 
" Tolerised (100 μχ HEL) and control mice (PBS) were treated i.p. with anti-
IL-4, rat-IgG or PBS, by employing 2 different administration protocols: 
1. around tolerance induction (3 times 1 mg Ab, on days -8, -5, and -2), 
2. around arthritis induction (2 times 1 mg Ab, on days 20, and 23). 
b
 Amounts of infiltrate and exudate were scored 7 days after arthritis induction 
on a scale ranging from 0 to 3. Data are expressed as the mean (± sd) of 8 
mice per group. 
Anti-IL-4 administration did not have effects on arthritis in the control group 
(PBS i.v.). When tolerised mice were treated with anti-IL-4, no abrogation of 
tolerance was seen in both protocols. This was also reflected in measurement 
of joint swelling (data not shown). Efficacy of anti-IL-4 treatment was checked 
by measuring subclasses of Ab-titres in sera (table 4). 
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Table 4. Effects of anti-IL-4 on antibody titres. 
Dilutionb 
Treatment3 IgG, IgG^ 
PBS / PBS 340 250 
PBS / anti-IL-4 120 440 
HEL / PBS 340 
HEL / anti-IL-4 90 200 
a
 Effects of anti-IL-4 administration (days -8,-5,-2) on HEL-specific IgG,- and 
IgG^-titres in sera of control and tolerised mice. 
h
 Ab titres are expressed as the dilution where half maximal extinction is 
reached (mean of 7 different mice per group). Standard deviations never 
exceed one dilution step. 
IgE-titres were not detectable in all groups, and could therefore not be used to 
test anti-IL-4 activity. However, the raise in IgG^- and drop in IgG,-titres in 
controls as well as in tolerant mice clearly demonstrate efficacy of anti-IL-4 
treatment. 
Further investigations were focussed on the reduced proliferative capacity and 
IL-2 production seen in vitro (table 1). The potential role of suppressive 
soluble factors was studied by adding Ab against IL-4, IL-10, and TGF/S. 
Administration of anti-IL-10 and anti-TGF/3 could not abrogate the reduced 
proliferative capacity and IL-2 production in tolerised mice. Anti-IL-4 reduced 
proliferative responses both in control and tolerised LNC, whereas IL-2 
production was not influenced. All control Ab did not have any effect on 
proliferation and IL-2 production (data not shown). 
Anergy of T-lymphocytes as explanation for i.v. induced tolerance 
All in vivo and in vitro experiments performed, were unable to explain the 
mechanism of i.v. induced tolerance. The tolerance was antigen-specific and 
systemic. It was not caused by active suppression by CD8+-cells or by 
induction of Th2-cells. T-cell anergy, as postulated by others111718 remained as 
a possible mechanism. 
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Tolerised and control LNC were cultured for 5 days in the presence of rmIL-2. 
Proliferation assays were performed just before and 5 days after rIL-2 
stimulation. In this way reversibility of anergy could be tested. Table 5 shows 
results of proliferative responses on HEL and con A. 
As shown before, antigen-specific proliferative responses, measured in short 
term culture studies are suppressed in tolerised mice. However, after 
stimulation in vitro by rIL-2 for 5 days, both groups develop almost identical 
responses on antigen. This means that HEL-specific T-cells are present in 
tolerised mice, but they most likely are in an anergic state. This state of 
anergy can be reversed by rIL-2 stimulation. 
Table 5. Reversal of anergy by rIL-2 stimulation. 
Antigen-cone. 
Oig/ml) 
medium 
HEL 5 
HEL 25 
HEL 50 
HEL 100 
HEL 250 
con A 2.5 
con A 1.25 
Direct' 
control3 
102 cpm 
11 
21 
22 
23 
23 
446 
373 
tolerisedb 
92 cpm 
3 
7 
10 
4 
5 
580 
460 
Stimulation 
rIL-2 (5 d)c 
control 
220 cpm 
11 
12 
22 
15 
20 
339 
192 
tolerised 
216 cpm 
7 
11 
14 
17 
17 
538 
406 
" Control mice received PBS i. v. 7 days before immunisation. 
b
 Mice were tolerised by i. v. injection of 100 μ# HEL 7 days before 
immunisation. 
c
 Reversal of anergy was studied by performing proliferation assays of LNC 
from tolerised and control mice. Antigen-specific responses were measured 
directly after isolation ofLN, and after 5 days in vitro stimulation with rIL-2 
(50 U/ml). Results are expressed as stimulation indices, besides values of 
medium (counts per minute). 
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DISCUSSION 
In the present study, underlying mechanisms of i.v. induced tolerance in an 
antigen-induced arthritis were investigated. Three plausible mechanisms were 
examined: active suppression by CD8+ T-lymphocytes5"8, suppression by Th2-
cells or produced factors9"16, and anergy of antigen-specific lymphocytes.111718 
Tolerance induction by i.v. administration can be demonstrated in vitro as well 
as in v/vc».1"5,34 Our results clearly show that i.v. injection of HEL before 
immunisation can abrogate an antigen-induced arthritis. Joint swelling, 
infiltrate and exudate were almost completely suppressed. Cartilage 
proteoglycan depletion was significantly reduced in tolerised mice. 
CD8+ suppressor cells have been shown to be important in suppression of 
autoimmune diseases such as experimental autoimmune encephalomyelitis 
(EAE) and orchitis.5·6 8 Suppression after multiple oral feedings of 1 mg MBP 
could be transfered by con Α-activated CD8+ T-lymphocytes.6 Identical results 
were reported by Mukasa et al.5 when lx IO7 CD8 + T-lymphocytes, obtained 
after 5 i.v. administrations of 1 mg murine testicular antigen, were transfered 
to naive animals. Wilbanks et al.1 demonstrated that tolerance induction with a 
protein antigen (50 μg BSA) via the anterior chamber of the eye, could partly 
be abrogated via anti-CD8 treatment. In our studies, in vivo anti-CD8 
treatment could not abrogate tolerance, indicating that in our system of i.v. 
induced tolerance, CD8* cells do not play an important role. This prompted 
us to look for other possible mechanisms. 
In vitro results showed antigen-specific inhibition of proliferative responses 
and IL-2 production in tolerant LNC. IL-4 production was in four out of five 
experiments below detection level, and inhibited in one experiment in the 
tolerant group. This in contrast to studies of i.p. induced tolerance, where 
likewise suppression of the Thl-subset was measured, but clear stimulation of 
Th2-cells as well. In the latter experiments, proliferative responses as well as 
IL-2 and IFN7 production were diminished, whereas IL-4 production was 
stimulated.1113,35 As an in vivo reflection of stimulation of IL-4, a shift was 
noted in antibody response. IgG, and IgE were equal or slightly increased, 
while IgG^ and IgG
:b were suppressed in tolerised mice. Our data concerning 
different antigen-specific subclasses of Ab show the same trend. IgG, was 
unchanged, and IgG^ was diminished in tolerised mice. IgM, IgE and IgG.,b 
were low in controls as well as tolerised mice. Taken together, the role of 
Th2-cells remained unclear. Therefore, in vivo anti-IL-4 studies were carried 
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out. Others have demonstrated that anti-IL-4-treatment in vivo abrogated i.p. 
induced tolerance of Thl-cells and influenced subclasses of Ab-titres.11·12·36 
Burstein et al.n showed Thl-cell activation by in vitro IFNY stimulation, while 
IL-2 production remained reduced. The potential role of IL-4 in our model 
was tested in two different anti-IL-4 administration protocols. Effects were 
measured in an in vivo read-out system. The results showed no abrogation of 
tolerance by anti-IL-4 administered either around the time of tolerance 
induction or around the time of arthritis induction. Efficacy of anti-IL-4 
treatment was demonstrated by measuring Ab-titres: IgG^-titres raised and 
IgG,-titres dropped in controls as well as tolerised mice. Reduced proliferative 
responses and IL-2 production in tolerised mice remained reduced after anti-
IL-4 treatment (data not shown). This failure of abrogating tolerance seems to 
be in contrast with data of others11-36, although Burstein et al.n also saw no 
effects of anti-IL-4 treatment on IL-2 production. Apparently, IL-4 seems to 
be involved in regulation of subclasses of antibodies, but is not an important 
determinant in downregulation of Thl-cell induced joint inflammation. 
Not only IL-4, but also IL-10 and TGF/3 have been shown to play an 
important role in down-regulating Thl-cells.911·13"16 Miller et al.16 
demonstrated an enhanced expression of IL-4 and TGF/3 in the brains after 
feeding Major Basic Protein (MBP) before induction of EAE. TGF/3 was also 
produced in the same model after in vitro stimulation of tolerised spleen cells 
with MBP.15 De Wit et α/.13 showed that i.p. injection of 1 mg monomeric, 
deaggregated human gamma globulin led to enhanced IL-4 production and 
reduced IL-2 and IFN7 production of draining LNC. The role of soluble 
immunosuppressive cytokines in vitro was studied in our system. In 
experiments where Ab against IL-4, IL-10 or TGF/3 were administered, no 
abrogation of reduced proliferative responses and IL-2 production could be 
measured. Anti-IL-4 reduced proliferative responses of control and tolerant 
LNC, while no influence was exerted on IL-2 production. This is likely due to 
inactivation of antigen-specific Th2 cells, which may contribute to proliferative 
response and not to IL-2 production. From these data we conclude that 
activation of the Th2-subset does not play a dominant role in i.v.-induced 
tolerance. 
The third hypothesis, anergy of antigen-specific T-lymphocytes, has also been 
proposed by other investigators.11,1718·24 Melamed et al.11 provided direct 
evidence for anergy after feeding one dose of 20 mg OVA before 
immunisation. This state of anergy could be partly reversed by rIL-2 
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stimulation. Feeding very high amounts of antigen might lead to transfer of 
OVA to blood.17 This situation resembles injection of small amounts of antigen 
i.v. or i.p.. Such conditions are thought to favor anergy induction.17 This was 
also shown by Burstein et α/." after i.p. administration of aqueous antigen. 
However, when antigen is fed in small amounts, induction of suppression 
might be favored.1517 Beverly et al.2i demonstrated that reversal of anergy 
could even be complete. Anergy was generated in vitro by con A-stimulation 
in the absence of APC. However, stimulation with 30 U rIL-2/ml resulted in 
complete reversal of the anergic state.24 In our hands rIL-2 stimulation (50 
U/ml) in vitro for five days completely reversed antigen-specific proliferative 
responses of tolerised LNC back to control responses. We therefore conclude 
that anergy of antigen-specific Τ lymphocytes is an important mechanism in 
our model of iv-induced tolerance. 
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CHAPTER 7 
ROLE OF IL-2 AND IL-4 IN EXACERBATIONS OF MURINE 
ANTIGEN INDUCED ARTHRITIS 
Marike J.M. Jacobs, Astrid E.M. van den Hoek, Peter L.E.M. van Lent, 
Fons A.J. van de Loo, Levinus B.A. van de Putte & Wim В. van den Berg 
Immunology, in press 
SUMMARY 
In this study the role of different T-cell subsets, and produced cytokines were 
investigated in an animal model for acute exacerbations. Flare-up reactions are 
inducible in the chronic phase of a smouldering antigen induced inflammation 
by injection of a small amount of an antigen into a hyperreactive knee joint. 
In vivo treatment with anti-CD4 monoclonal antibodies (Ab) almost totally 
blocked the flare reaction, whereas anti-CD8 treatment did not exert any 
effect. The role of Thelper 1 (Thl) cells in delayed type hypersensitivity 
resembling diseases is generally entitled pro-inflammatory, whereas Th2 cells 
act anti-inflammatory. To investigate the role of these T-cell subsets in flare-
up reactions, anti-IL-2 and anti-IL-4 monoclonal Ab treatments were 
performed. Anti-IL-2 treatment partly blocked the flare reaction, and anti-IL-4 
treatment, although unexpected, even blocked the flare more efficiently. 
Furthermore, when human recombinant IL-2 (hrIL-2) and murine recombinant 
IL-4 (mrIL-4) were coinjected with the antigen to test their ability resp. to 
potentiate or down-regulate the flare reaction, both cytokines demonstrated 
additional pro-inflammatory effects, although hrIL-2 was more potent than 
mrIL-4. The mere effect of hrIL-2 and mrIL-4 was studied by direct injection 
into a hyperreactive joint. No flare-up reaction or cell-influx could be induced, 
suggesting that other mediators are needed to exert pro-inflammatory effects of 
IL-2 or IL-4. 
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We conclude that not only ТЫ cells, but also Th2 lymphocytes (at least 
regarding IL-4 production) may play an pro-inflammatory role in flare-up 
reactions of chronic arthritis. Considering therapeutic application of Th2-cell 
derived cytokines, one should be aware of possible pro-inflammatory 
potentials of IL-4. 
INTRODUCTION 
Mouse CD4+ Τ cells can be subdivided into two subclasses. Thl cells produce 
the autocrine growth factor IL-2, and ΙΡΝγ, and appear to promote delayed 
type hypersensitivity (DTH) reactions. Th2 cells secrete IL-3, IL-4 (autocrine 
growth factor), IL-5, and IL-10, which are elevated in allergic diseases and 
parasitic infections.1"5 IL-4 may exert anti-inflammatory effects directly on Thl 
cells or via inhibition of macrophage APC function. Furthermore, IL-4 is 
capable of inhibiting monocytes in their production of inflammatory cytokines 
e.g. IL-1, IL-6, and TNFa, whereas IL-lra production will be 
upregulated.2'3'6·7 
On the other hand, IL-4 may exert pro-inflammatory effects. It was 
demonstrated that IL-4 is chemotactic for macrophages, in contrast to IL-2 and 
IFN7.8 Furthermore, IL-4 can induce the expression of adhesion molecules on 
endothelial cells. Vascular cell adhesion molecule-1 (VCAM-1) expression was 
demonstrated to be upregulated by IL-4 stimulation, and as a result an 
increased adherence of lymphocytes, eosinophils and basophils was seen.9"11 
IL-4 can also be produced by basophils and mast cells, which on their turn can 
be activated by IL-4.12"14 Müller et al. demonstrated clear pro-inflammatory 
effects of Th2 cells.15 Not only polyclonal murine Thl, but Th2 cells as well 
were capable of mediating tissue inflammation in vivo. The inflammatory 
response induced by Th2 cells could be blocked with monoclonal Ab to IL-4 
or soluble IL-4 receptor. 
Human rheumatoid arthritis is characterised by a fluctuating disease course 
with sometimes acute exacerbations superponed on the chronic inflammatory 
process. In the present study the contribution of Thl and Th2 cells was studied 
in an animal model of arthritis mimicking these acute exacerbations. Flare-up 
reactions were induced by systemic administration of a sufficient amount of 
antigen or by local administration of a small amount of antigen in the chronic 
phase of a smouldering arthritis. Only in this phase of local hyperreactivity, 
IL-2 and IL-4 in exacerbations 109 
when low-grade of predominantly mononuclear cells are left in the synovium, 
flare-up reactions can be induced.16"30 An important role of T-lymphocytes in 
this phenomenon was underscored by treatment with anti-lymphocyte serum 
and monoclonal anti-la-antibodies.21·22 The role of different T-cell subsets in 
flare-up reactions has never been investigated. Although the involvement of 
Thl cells was expected to be pro-inflammatory, and the role of Th2 cells to be 
anti-inflammatory and probably involved in down-modulation of the flare, 
such experiments have never been carried out. We therefore investigated the 
role of Thl and Th2 cell subsets indirectly by aIL-2 and aIL-4 treatments. 
Data show that the exacerbation could be partly blocked by both antibodies. 
Furthermore human recombinant IL-2 (hrIL-2) and murine recombinant IL-4 
(mrIL-4) were tested in their ability to potentiate flare-up reactions. hrIL-2 and 
in a lesser extent mrIL-4 were able to potentiate a flare. These findings 
indicate not only a role for Thl-cells, but also an additive (or even more 
important) role for Th2-cells. Considering Th2-cell derived cytokines for 
therapeutic purposes, one should be aware of the pro-inflammatory potentials 
of IL-4. 
MATERIALS AND METHODS 
Animals. 
Female C57Bl/6-mice, aged 12-14 weeks, were bred in the Central Animal 
Laboratory. 
Materials. 
Hen egg lysozyme (grade I)(HEL), 1-ethyl 3(3-dimethyl-aminopropyl) car-
bodiimine hydroxychloride (EDC), poly-L-lysine (56 kD)(PLL), and ratlgG 
were obtained from Sigma (St. Louis, MO, USA). To raise MW, HEL was 
coupled to PLL using EDC as activator. Coupled PLL was separated from 
free HEL by Sephadex G75 gel filtration. The ratio HEL/PLL in coupled 
product was found to be l.22 Monoclonal Ab produced by S4B6- (aIL-2), 
1 IBI 1- (aIL-4), 2.43 (aCD8), and GK1.5 (aCD4) hybridomas (obtained from 
American Type Culture Collection, Rockville, MD) were purified by HPLC-
technique, using a protein G column. Murine recombinant IL-2 was obtained 
from Genzyme (Boston, MA). Human recombinant IL-2 was kindly provided 
by Proleukin, and murine recombinant IL-4 was a gift from Immunex (USA). 
по 
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Immunisation. 
Mice were immunised in the footpads of the forelegs and subcutaneously (sc) 
in the flanks with 200 μg antigen emulsified in Complete Freund's Adjuvant 
(CFA)(Difco, Detroit, MI, USA). Additionally, 2x10' heat-killed Bordetella 
pertussis organisms (National Institute of Public Health, Bilthoven, the 
Netherlands) were administered intraperitoneally (i.p.)· Seven days later 
booster injections were given sc (150 ^g antigen/CFA). 
Arthritis and flare-up induction. 
Mice were injected intra-articularly (ia) in the right knee joint with 30 μg 
PLL.HEL in 6 μΐ PBS, 21 days after the first immunisation. Joint 
inflammation was determined until recovery by measurement of T c 
pertechnetate uptake of the knee joint. Mice were sedated with chloral hydrate 
(intraperitoneally) and injected subcutaneously in the neck region with 10 μΟΐ 
W mTc. After 20 min, radioactivity was assessed by measuring both knees in a 
fixed position. Joint swelling was expressed as the ratio of the " T c uptake in 
the left and right knee joints (L/R ratio).23 
After 4 to 5 weeks, when arthritis had almost recovered, a flare-up reaction 
was induced by injecting 2 μg PLL.HEL into the hyperreactive joint. 24 
Hours later joint-swelling was measured, and mice were sacrificed to perform 
histology. Joint-swelling is expressed as delta (δ): L/R-ratio in experimental 
group minus L/R-ratio in PBS-injected group. 
Histology. 
Groups of at least 6 mice were killed 24 hours after flare-up induction. Knee 
joints were dissected and processed for histology, as described previously.24 
Whole knee joint sections (6 μπι) were prepared and stained with 
haematoxylin/eosin. Arthritis was scored semiquantitatively double blind in a 
standardised frontal section of the knee joint which included menisci, cruciate 
ligaments and patella. Extent of cellular infiltration of synovial tissue, and 
cellular exudate in the joint space were graded on a scale ranging from 0 (no 
cells) to 3 (dense cell infiltrate and/or exudate). 
Cytokine administration. 
Effects of human recombinant IL-2 (hrIL-2) and murine recombinant IL-4 
(mrIL-4) were studied by coinjection of 2 μg PLL.HEL and 1000, 200 or 40 
U hrIL-2, or coinjection of 2 μg PLL.HEL and 1000 or 200 U mrIL-4. 
IL-2 and lL-4 in exacerbations 111 
Besides, equal amounts of the cytokines were injected into a hyperreactive 
knee joint without 2 μg antigen. 
Ab-treatment. 
For anti-CD4 and anti-CD8 mAb-treatments, animals were given 3 i.p. 
injections of resp. 100 μg HPLC-purified GK1.5, or 2.43 in PBS on days -3, -
2, and -1 before flare-induction. This dose of GK1.5 and 2.43 has been shown 
to deplete >99% of resp. CD4* or CD8+ T-lymphocytes.^26 
For anti-IL-2, or anti-IL-4 mAb-treatments, mice were given i.p. injections of 
1 mg HPLC-purified S4B6, or 1 IBI 1 in PBS on day -2 before and on the day 
of flare-induction. Control animals were given equal amounts of rat-IgG or 
PBS alone. The capacity of 1 mg anti-IL-2 to neutralise mrIL-2 in vitro, as 
measured by a CTLL-assay, was 250 U.27 The neutralising capacity of 1 mg 
anti-IL-4 was 2000 U mrIL-4, as measured by a CT.4S-assay.28 
Statistics. 
Results are expressed as mean + sd. Statistical significance was tested by 
using the Wilcoxon's rank sum test. P< 0.05 (*) was considered significant. 
RESULTS 
Induction of flare-up reactions and the role of T-lymphocytes 
Four to five weeks after induction of a primary arthritis by injecting 30 ^g 
PLL.HEL into the knee joint, arthritis seems to be almost recovered, but in 
the synovium a low-grade of predominantly mononuclear cells are left. At this 
time flare-up reactions can be induced by injecting a small amount of 
PLL.HEL (2 μg) into such a hyperreactive knee joint. Figure 1 shows that 
joint-swelling peaks 24 hours after flare-induction, and thereafter rapidly 
decreases to almost normal at 72 hours. Injection of 2 μg PLL.HEL into naive 
joints induced minor inflammation (figure 1). In following studies mice were 
sacrificed at 24 hours after flare-induction. 
The roles of CD4~ and CD8" T-lymphocytes were examined by treating mice 
on days -3, -2, and -1 before flare-induction with 100 μ% anti-CD4, anti-CD8, 
or anti-CD4 + anti-CD8 antibodies (Ab). Efficacy of antibody-treatment was 
determined one day after flare-induction by counting the number of CD4+ and 
CD8+ cells in spleen and draining lymph nodes, and amounted never more 
than 1.5% after specific Ab treatment. Control mice received rat-IgG or PBS. 
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Figure 1. Course of joint-swelling in time after i.a. injection of 2 μ# 
PLL.HEL in a hyperreactive knee joint (black bars) and a naive joint (hatched 
bars). Joint swelling is expressed as the mean (± s.d.) ofL/R ratios of eight 
mice per group, minus the background swelling before flare-induction. 
Results in figure 2a show that anti-CD4 treatment alone and combined anti-
CD4/anti-CD8 treatment blocked the exacerbation. Treatment with rat-IgG, or 
anti-CD8 Ab did not affect the exacerbation. This was also reflected in 
histological findings (figure 2b), and leads to the conclusion that CD4+ T-
lymphocytes are important in flare-up reactions. 
Role of IL-2 and IL-4 
The potential role of CD4+ Thelper 1 (Thl) and Thelper 2 (Th2) subsets was 
studied by anti-IL-2 or anti-IL-4 treatment. Antibodies (1 mg) were 
administered two days before and on the day of flare-induction. When mice 
were treated with anti-IL-2, a marginal reduction (p=0.055) in joint-swelling 
was seen (figure 3a). However, histological findings demonstrated a significant 
reduction (p = 0.016) in the amount of cell exudate (figure 3b). To our 
surprise, anti-IL-4 treatment was very effective in reducing joint-swelling, and 
also the infiltrate and exudate were markedly reduced (figures 3a, 3b). Out of 
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these data one may conclude that not only IL-2, but also IL-4 contributes to 
the inflammation seen in flare-up reactions. 
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Figure 2. Effects ofanti-CD4, anti-CD8 or anti-CD4 + anti-CD8 treatment 
on (a) joint-swelling, and (b) the amount of cell exudate (black bars) and 
infiltrate (hatched bars) in a flare-up reaction (24 h). Antibodies (100 ßg) 
were administered i.p. on days -3, -2 and -I before flare induction. Controls 
received PBS or rat-IgG. The joint swelling is the mean (± s.d.) ofL/R ratios 
of seven mice per group, minus the swelling as measured in PBS injected in 
hyperreactive joints (L/R ratio = 1.19). Histology was scored 24 hours after 
flare induction on a scale ranging from 0 to 3. The background (BG) 
inflammation was scored just before flare induction. Data are expressed as the 
mean (± s.d.) of seven mice per group. * P< 0.05 
Not only Th2 cells produce IL-4, but also mast cells are potential IL-4 
producers. The amount of mast cells was studied before and after flare-
induction in antibody treated as well as untreated groups (Giemsa staining). 
Small numbers of mast cells were seen in the chronic smouldering arthritis, 
mainly situated subcutaneously, and not close to the joint space. After 
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induction of the flare by i.a. injection we did not observe degranulation of 
cells, nor was the acute infiltrate situated around these mast cells. Similar 
pictures were noted in the antibody treated groups. This suggests that the role 
of mast cells is not an important one, and that not only the pro-inflammatory 
Thl, but also the Th2-cell subset, generally described as anti-inflammatory, is 
involved in flare-up reactions. 
0 80 
0.70 
0.60 
0.50 
0.40 
0.30 
0.20 
0 10 
0.00 
δ flare-up 
(a! 
score (24 hr) 
Cb) 
flare rlgG aIL-2 aIL-4 
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Figure 3. Effects of anti-IL-2 or anti-IL-4 treatment on (a) joint-swelling, and 
(b) the amount of cell exudate (black bars), and infiltrate (hatched bars) in a 
flare-up reaction. Antibodies (1 mg) were administered i.p. two days before 
and on the day of flare induction. Controls received PBS (= flare) or rat-IgG. 
The joint swelling is the mean (± s.d.) ofL/R ratios of eight mice per group, 
minus the swelling as measured in PBS injected in hyperreactive joints (L/R 
ratio = 1.21). Histology was scored 24 hours after flare induction on a scale 
ranging from 0 to 3. The background (BG) inflammation was scored just 
before flare induction. Data are expressed as the mean (± s.d.) of eight mice 
per group. * P< 0.05 
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The potential capacities of IL-2 to induce an exacerbation, and of IL-4 to act 
anti-inflammatory, were further studied by coinjection of the cytokines 
together with 2 μg PLL.HEL. When 1000 U or 200 U hrIL-2 were coinjected 
with the antigen, both concentrations exerted significant additional effects on 
the amount of cell infiltrate and exudate compared to injection with 2 μg 
PLL.HEL alone. No additional effects were seen by coinjection with 40 U 
hrIL-2, or a control protein (BSA)(data not shown). Coinjection of PLL.HEL 
with 1000 U mrIL-4 showed totally no suppression of the flare. In contrast, 
the amount of cell infiltrate increased significantly, whereas the exudate 
showed an enhancement, not reaching significance as compared to the control 
flare (figure 4). When lower amounts of mrIL-4 (500 U, 200 U) were 
coinjected, no additional effects were demonstrated (data not shown). 
score (24 hr) 
3.00 • 
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2.50 • 
BG fleie 1000 U IL-2 200 U IL-2 1000 U IL-4 
t r e a t m e n t 
Figure 4. Effects of coinjection of hrIL-2 or mrIL-4 with 2 ßg PLL.HEL on 
the amount of cell exudate (black bars), and infiltrate (hatched bars). 
Histology was scored 24 hours after flare induction on a scale ranging from 0 
to 3. The background (BG) inflammation was scored just before flare 
induction. Data are expressed as the mean (± s.d.) of eight mice per group. 
* P< 0.05 
Finally, the mere effect of cytokines was studied by direct injection in a 
hyperreactive joint. No flare-up reaction could be induced, when either 1000 
U IL-2 or 1000 U IL-4 were injected without antigen. No joint-swelling could 
116 Chapter 7 
be measured, and no influx of cells was seen (data not shown). This suggests 
that the pro-inflammatory action of these cytokines in the antigen-driven flare 
is due to a synergism with other mediators, or acts via the generation of other 
cytokines. Only in case sufficient inflammatory cells are attracted to the joint 
space, cytokines like IL-1 and TNFa can be produced in larger amounts. 
DISCUSSION 
In this study we investigated the role of T-lymphocytes, and the cytokines IL-2 
and IL-4 in flare-up reactions. Flare-up reactions were generated in a chronic 
smouldering phase of an antigen-induced arthritis by local injection of small 
amounts of antigen into the knee joint. An advantage of local injection versus 
i.v. or oral administration1^" is that an exact amount of antigen reaches the 
knee joint. Moreover, in case high circulating antibody titres exist (depending 
on the type of antigen), i.v. administration of an antigen may cause massive 
immune-complexe formation leading to a lethal shock. Local injection of 
PLL.HEL causes an irritating effect, leading to a mild background 
inflammation in naive joints of immune mice (figure 1). To discriminate 
optimally between the flare reaction and the background, we decided to inject 
2 /ig PLL.HEL, and sacrifice the mice 24 hours after flare induction. 
In previous reports the role of T-lymphocytes in an i.v. mBSA induced 
exacerbation was already demonstrated by treatment with anti-lymphocyte 
serum and monoclonal anti la-antibodies.20,21 This in agreement with data 
obtained after aCD4 treatment in various experimental autoimmune diseases, 
where suppression could be generated in autoimmune thyroiditis29, 
proteoglycan aggrecan induced arthritis30, experimental autoimmune 
encephalomyelitis (EAE)31, and collagen-induced arthritis.32 The role of CD8+ 
cells remains less clear. In remission of EAE, CD8* cells play a down-
regulating role33,34, although CD8+ cell depletion did not affect the disease.35 
In a proteoglycan aggrecan-induced arthritis on the contrary, severity of 
disease was enhanced by CD8+ T-cell depletion.30 Most antibody treatments 
were performed early during disease induction. We decided to treat mice just 
before flare induction, in order to leave the building up phase of immunity 
intact. Results (figure 2) showed that depletion of CD4+ cells abrogated the 
flare-up reaction drastically, whereas depletion of CD8+ cells had no effect, 
suggesting that CD8+ cells do not play an important role in down-regulation of 
the flare-reaction. 
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The involvement of CD4+ ТЫ and Th2 cells was indirectly studied by 
antibody treatments to the respectively autocrine growth factors IL-2 and IL-4. 
We expected a down-regulation of the flare reaction by blocking IL-2. The 
role of IL-4, as described in many reports2·3·36,37, was expected to be anti­
inflammatory. The generation of Th2 cells, and produced cytokines might be 
an important mechanism for remission of the flare reaction. These 
phenomenons have been described for EAE and experimental autoimmune 
uveoretinitis34-38·39 Therefore, blocking of IL-4 was expected to prolong and/or 
worsen disease activity. Results (figure 3) show that anti-IL-2 treatment partly 
blocked the flare-reaction, whereas to our surprise anti-IL-4 treatment was 
even more effective in blocking joint swelling and cell influx. In case 
cytokines were coinjected with the antigen, additional pro-inflammatory effects 
were demonstrated for hrIL-2. Similarly, coinjection with mrIL-4 showed up 
to be pro-inflammatory, although in a lesser extend than IL-2 (figure 4). These 
findings might be explained by higher local amounts of endogenous IL-4, as 
compared to IL-2. The mere effect of these cytokines when injected in a 
hyperreactive joint could not induce any inflammation. Therefore, we think 
that the pro-inflammatory action of IL-2 and IL-4 might be due to induction or 
synergism with other mediators like IL-1 or TNFa. The capacity to induce 
flare-up reactions with injection of only IL-1 or TNFa have already been 
demonstrated (unpublished data).40 These cytokines will only be produced in 
large amounts when sufficient inflammatory cells are attracted to the joint 
space. 
Several notes can be made in order to explain these unexpected findings. First, 
the capacity of anti-IL-4 Ab to block mrIL-4 was better than the capacity of 
anti-IL-2 to neutralise mrIL-2 in vitro. It therefore might be that the used anti-
IL-2 Ab concentration, although comparible to others41"44 was not sufficient. 
On the other hand, even the use of a double dose of anti-IL-2 exerted no 
additional effects in blocking the flare reaction (data not shown). Moreover, 
the knowledge concerning local cytokine amounts in inflammation is limited, 
and therefore the choice of Ab doses remains difficult. Secondly, also mast 
cells produce IL-4, and can be activated themselves by IL-4.12"14·45 In case 
these mast cells play an important role in flare-up reactions, blocking by anti-
IL-4 could reflect inactivation of mast cells instead of blocking specific Th2 
cell functions. The role of mast cells in antigen-induced arthritis and flare-up 
reactions induced by mBSA has been studied by others. Tiggelman et al.*6 
concluded that mast cells do not play a significant role in the inflammatory 
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process during the early phase of arthritis. Lens et al.47 demonstrated that the 
number of mast cells before and after flare induction was equal and these cells 
were situated predominantly in the periarticular tissue. On the other hand, 
studies in mast cell deficient mice indicated that mast cells may play an 
enhancing role in the flare reaction.48 We also performed stainings to study the 
number of mast cells in control and antibody treated mice. Only low and equal 
numbers of mast cells in all groups could be demonstrated, indicating that no 
significant degranulation took place. Moreover, these mast cells were always 
situated far from the joint space, and no acute infiltrate was situated around 
these mast cells. These data suggest that the inactivation of mast cells can not 
explain the effects seen after anti-IL-4 treatment. In the third place, IL-4 can 
have pro-inflammatory effects by upregulation of VCAM-1 expression on 
endothelial cells, and as a result an increased adherence of lymphocytes, 
eosinophils and basophils.9"" Furthermore, chemotactic effects of IL-4 were 
demonstrated on macrophages.8 A reduced cell influx by anti-IL-4 treatment, 
as seen in our experiments, might be partly explained by these effects. 
In the fourth place, studies have been reported in which the addition of IL-4 is 
important to enhance the IL-2 production by Thl cells.49"51 This stimulating 
effect on activated Τ cells was detectable within 6 to 8 h after restimulation, 
and could be blocked in vitro by anti-IL-4 Ab.49 The same kind of 
observations were done by Fanslow et al.52 and ourselves (unpublished data). 
When mice were immunised with HEL/CFA, and in vitro lymphocyte 
stimulation tests were performed, proliferation could be blocked by anti-IL-2 
as well as anti-IL-4 Ab, whereas IL-2 production was only inhibited by anti-
IL-2 Ab. This means that or IL-4 can act as a costimulator for Thl cells, or 
that Th2 cells themselves contribute to the response on a particular antigen. 
The in vivo role of Th2 cells in inflammatory processes might therefore not 
always be anti-inflammatory. Pro-inflammatory effects of Th2 cells, peaking 
after 6 h and lasting up to 48 h, were also demonstrated by Müller et α/.15 
These effects could be abrogated by anti-IL-4 treatments, van der Veen and 
Stohlman" showed, that in remission of EAE Th2 were recruited, exerting 
their effects via IL-10 production, whereas IL-4 had no effect on inhibition. 
Our data suggest that the role of Th2 cells may be, in regard to IL-4 
production, pro-inflammatory. Considering the Th2-cell derived cytokine IL-4 
for therapeutic purposes, one should be aware of the pro-inflammatory 
potentials. 
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CHAPTER 8 
SUMMARY AND FINAL REMARKS 
In this thesis different ways of in vivo modulation of T-cell immunity are 
described. These include T-cell vaccination, oral and intravenous induction of 
tolerance, and specific monoclonal antibody treatments. The role of different 
T-cell subsets, and produced cytokines have been studied to get insight in 
underlying mechanisms. 
In chapter 2 the feasibility of T-cell vaccination was tested using antigen-
specific bulk lymph node cells (LNC) as a vaccin. A disadvantage of this 
approach is that only a low amount of antigen-specific cells are present. 
Others mainly used antigen-specific lines or clones, and demonstrated that T-
cell vaccination was effective in several experimental autoimmune models. 
They state that a pre-requisite for successful vaccination is the presence of pre-
existing anti-idiotypic networks, developed during differentiation of the 
immune system as a safeguard against autoimmune diseases. When activated 
non-specific cells are used as vaccin, these create an anti-ergotypic network, 
which may also contribute to suppression.1"6 We tested the feasibility of T-cell 
vaccination in an immunity directed to foreign protein antigens. Our data show 
that ovalbumin (OVA)- and HEL-specific delayed type hypersensitivity 
responses (DTH) could be suppressed by treatment before immunisation with 
glutardialdehyde treated OVA-specific and HEL-specific LNC respectively. 
This indicates that no pre-existing anti-idiotypic network has to be present. We 
did not find anti-ergotypic modulation. On the other hand, when vaccination 
was tested with methylated bovine serum albumin (mBSA)-specific LNC in 
mBSA-immunity, no suppression could be induced. No encouraging data were 
obtained in pilot experiments, in which treatments were performed after 
immunisation, suggesting that an ongoing immunity is difficult to modulate. At 
this moment the usefulness of the procedure of T-cell vaccination in human 
rheumatoid arthritis is uncertain. Complicating factors are that the disease is 
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already going on and the putative antigen is unknown. Clinical investigations 
in RA patients have been carried out, but results are not very promising. 
The interesting finding that the degree of suppression may depend on the type 
of antigen involved, was also demonstrated in orally and intravenously (i.v.) 
induced tolerance (chapter 3). The native proteins OVA and BSA, when 
feeded seven days before immunisation, induced antigen-specific reductions in 
DTH responses. In contrast, using their cationic derivatives mBSA, amidated 
BSA (aBSA) and aOVA, no suppression could be generated by oral feeding. 
Cross-studies showed that feeding aOVA in an OVA-immunity generated no 
suppression, whereas feeding OVA in an aOVA-immunity partly suppressed 
DTH-responses. The degree of cationicity may account for differences in 
absorbance of antigen by the gut, although others showed that cationic proteins 
do reach the circulation after oral feeding.7·8 I.v. tolerance induction of OVA 
was marked at low doses. Again, aOVA differed in capacity to induce 
tolerance, but at high doses a partial suppression was seen. Chemical 
modification of antigens may generate new epitopes and mask original 
epitopes, which may result in a disturbed balance of suppressor and 
stimulatory epitopes.9"11 Muckerheide et al.12 speculated that alteration of 
protein antigens like cationisation might change the affinity for antigen 
presenting cells or for the Τ cell receptor, resulting in different immunogenic 
properties. However, more recent developments in the field of immunology 
indicate that the form of antigen determines the generation of predominantly 
Thl or Th2 cells. It may therefore be possible, at the level of the repertoire, 
to manipulate the response towards a specific pattern of cytokine expression 
and consequently to control the response. The explanation for these observed 
findings is not clear, but an intriguing hypothesis is that some antigens are 
presented by В cells (favouring development of Th2-dominated responses) 
whereas other type of antigens are presented by macrophages (favouring Th 1 
responses).131} 
Moreover, mechanisms responsible for orally induced tolerance may differ 
from those responsible for i.v. induced tolerance.1617 The mechanisms 
responsible for orally induced tolerance were not studied in this thesis, in 
contrast to those involved in i.v. induced tolerance (chapter 6). Data from 
others indicate that orally administered antigens act predominantly via the 
generation of active suppression, whereas i.v. administered antigen induces 
anergy.'7'19 It would be interesting in the future to investigate the mechanisms 
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involved in our model system of orally induced tolerance, and compare 
different types of antigens. 
Clinical application of oral tolerisation in RA was recently reported in a phase 
II trial. The potential autoantigen collagen type II was feeded daily, and as a 
result significant improvements on disease score was seen.20 The question 
whether this treatment is antigen-specific or acting via antigen-driven 
bystander suppression remains to be answered. 
Our initial thoughts about suppressor epitopes was to modulate an immunity 
with these kind of epitopes more effectively and even in an already established 
immunity without risks for exacerbations. On the other hand, another vision 
supported by others, was to induce suppression with highly immunodominant 
epitopes.21"25 A way to generate in therapeutic epitopes was offered using 
endosomal/lysosomal proteases of antigen presenting cells, which have been 
demonstrated to be important to generate crucial peptides.26"29 
In chapter 4 the in vitro release of T-cell stimulatory peptides from hen egg 
lysozyme (HEL) by endosomal/lysosomal proteases cathepsin D and cathepsin 
В were tested. These naturally processed HEL-fragments were tested in their 
ability to stimulate T-cells from three strains of mice viz. BIO.A (H-2a), 
C57B1/6 (H-2b) and Balb/c (H-2d). Neither cathepsin В or D could cleave 
unreduced HEL, but reduced HEL was readily cleaved by cathepsin D but not 
by cathepsin B. Instead, cathepsin В was found active in the trimming of HEL 
peptides after their release by cathepsin D. When the cathepsin D processed 
peptides were tested in T-cell proliferation assays, a large number of peptides 
triggered significant responses. Strikingly, the response profiles of T-cells 
from the three different strains of mice showed marked similarities. This in 
contrast to earlier studies where specific T-cell epitopes were identified for 
various murine class II MHC backgrounds.30·31 Relatively short, and 
synthetically prepared peptides were tested as compared to our cathepsin D 
released fragments. Numerous observations have been described indicating that 
even small alterations in peptide structure may have significant effects upon 
the ability to bind to class II MHC molecules.3236 Our data suggest that the 
release of naturally processed, and relative long epitopes (in which cathepsin 
D plays a dominant role) may be more promiscuous than the relatively short 
synthetic peptides that are usually employed for epitope mapping. 
More recently the existence of specific suppressor epitopes has lost popularity, 
and new prospects and insights were gained in T-cells and mechanisms of 
tolerance induction. In chapter 5 and 6 effects of tolerance induction on an 
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antigen induced arthritis (AIA), and underlying mechanisms by i.v. 
administration of HEL before and after immunisation were studied. Arthritis 
and cartilage destruction were almost completely suppressed, as well as 
antigen-specific in vitro T-cell responses and IL-2 production, in case HEL 
was administered before immunisation. When HEL was injected after 
immunisation, only a marginal reduction in cell infiltrate and exudate was 
seen, whereas cartilage destruction was not affected. These data explain why 
so many reports describe antigen-specific immunomodulation before 
immunisation. This is disappointing, because in autoimmune diseases like RA 
there is always an established immunity, and besides the putative antigen is not 
known. Therefore, we tried to create a mechanism named antigen-driven 
bystander suppression. This was described by others in experimental 
autoimmune models by feeding an irrelevant antigen.37'39 In our experiments 
we administered HEL i.v. followed by triggering with HEL, in order to 
generate soluble suppressive factors like TGF/3. Unfortunately, this mechanism 
was not operative or was not powerful enough to suppress a mBSA-arthritis. 
Also experiments performed the other way around to suppress a HEL-arthritis, 
with mBSA driven bystander cytokines, were not successful. This does not 
implicate that there is no future for these kind of therapies, but in our model 
system of i.v. induced tolerance, bystander suppression could not be generated 
(chapter 5). 
In chapter 6 three plausible mechanisms of i.v. induced tolerance were 
investigated. Monoclonal antibody treatments directed to CD8+ T-lymphocytes 
in vitro as well as in vivo were not able to abrogate tolerance, indicating that 
antigen-specific CD8+ T-lymphocytes do not play a dominant role. The second 
possibility investigated was the generation of Th2 cell population, producers of 
suppressive cytokines like IL-4, IL-10, and TGF/3. Neutralisation of IL-4, IL-
IO or TGF/3 in vitro could not abolish T-cell tolerance as measured in 
proliferation assays. Also in vivo treatment with monoclonal antibodies to IL-4 
had no effect. These data indicate that a shift in Thl/Th2 cell balance probably 
is not the mechanism of tolerance induction. Therefore, a third possibility was 
tested: anergy of antigen-specific T-lymphocytes. Others demonstrated that a 
state of anergy results in reduced proliferative capacity and IL-2 production, 
and can be reversed in vitro by stimulation with rIL-2.40"42 We also 
demonstrated that proliferative capacity of antigen-specific T-lymphocytes of 
tolerised mice regained normal capacity to proliferate after five days in vitro 
stimulation with rIL-2. We conclude that i.v. induced tolerance most likely 
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results from anergy of antigen-specific T-lymphocytes. These results fit in the 
earlier mentioned hypothesis that i.v. induced tolerance by relative high doses 
of antigen favours anergy, whereas orally induced tolerance (relative low 
doses of antigen in the circulation) favours the generation of CD8+ T-
lymphocytes.17"19 Our results in chapter 6 may also explain why attempts to 
induce a system of antigen-driven bystander suppression were not successful 
after i.v. antigen administration. We now know that the mechanism involved 
is due to anergy of antigen-specific lymphocytes, in contrast to Ts cell 
generation in orally induced tolerance. Anergic cells are not able to generate 
suppressive factors like TGF/3, and therefore bystander suppression does not 
occur. 
In chapter 7 the role of Thl and Th2 cells was studied in flare-up reactions 
by modulation of IL-2 and IL-4. Interesting reasons to study a flare-up 
reaction is a potential difference in modulation of acute exacerbations as 
compared to primary induced arthritic processes. Besides, human rheumatoid 
arthritis is also characterised by exacerbations and remissions. Monoclonal 
antibodies directed to IL-2 or IL-4 were administered just before induction of 
the exacerbation. Anti-IL-2 treatment partly reduced joint swelling and cell 
exudate, whereas anti-IL-4 to our surprise even more effectively suppressed 
the flare reaction. Furthermore, coinjection of the antigen and recombinant 
human IL-2 or recombinant murine IL-4 both potentiated the exacerbation, 
although IL-2 was more effective then IL-4. Injection of the cytokines alone in 
a hyperreactive joint exerted no effects. IL-4, generally entitiled as anti-
inflammatory in DTH reactions, is not only produced by Th2 cells but also by 
mast cells.43"45 The contribution of these mast cells to arthritic processes and 
exacerbations is not clear. Some reports add a small role to mast cells46, 
whereas others do not.47 Histological data in our experiments indicate that only 
small numbers of mast cells are present in control as well as in anti-IL-4 
treated knee joints. They are mainly situated subcutaneously, and no acute 
infiltrate is situated around these mast cells. Therefore, we conclude that the 
role of mast cells is not an important one, and that not only Thl cells but 
probably also Th2 cells play a role in exacerbations. The question if Th2 cells 
also contribute to primary arthritic processes remains to be answered. 
Considering Th2 cell derived cytokines for therapeutic purposes, one should 
be aware of the pro-inflammatory potentials of IL-4. 
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SAMENVATTING 
Reumatoïde artritis (RA) is een frequent voorkomende systemische ziekte die 
zich kenmerkt door chronische ontsteking van de gewrichten. Het 
ziekteverloop is variabel: rustige periodes worden afgewisseld met periodes 
van actieve, soms heftige ontsteking (opvlamming). In het ontstekingsgebied 
worden meerdere typen ontstekingscellen aangetroffen, vnl. macrofagen, B- en 
T-lymfocyten. Deze cellen zijn in staat factoren (cytokines) uit te scheiden, die 
invloed kunnen uitoefenen op andere cellen. Dit kan resulteren in het 
aantrekken en activeren van andere cellen, met als gevolg een nog grotere 
cytokine productie. Deze overproductie van zogenaamde pro-inflammatoire 
cytokines kunnen schadelijke gevolgen hebben op omliggende weefsels. 
Tevens kunnen cellen anti-inflammatoire cytokines produceren, die belangrijk 
zijn in het remmen van ontstekingsprocessen. De balans tussen pro- en anti-
inflammatoire cytokines bepaald de mate en het verloop van een ontsteking. 
De regulerende rol die T-lymfocyten spelen blijft tot op dit moment 
onduidelijk. 
Een manier om ontstekingsprocessen, interventies hierin en achterliggende 
mechanismen te bestuderen, is het gebruik van experimentele 
proefdiermodellen. In dit proefschrift is gebruik gemaakt van een antigeen-
geïnduceerde artritis (AIA) in de muis. In dit model wordt een immuniteit 
opgewekt tegen een lichaamsvreemd eiwitantigeen door het antigeen toe te 
dienen in een emulsie. Tijdens immunisatie worden door B-lymfocyten 
antilichamen geproduceerd gericht tegen het eiwit, en ontwikkelen zich 
antigeen-specifieke T-lymfocyten. Na enige weken kan de immuniteit getest 
worden door een kleine hoeveelheid van het eiwit in het oor te spuiten, of in 
het knie gewricht. Er ontwikkelt zich een ontsteking, waarbij de mate van 
zwelling, en hoeveelheid celinflux een maat zijn voor de hoogte van de 
immuniteit. In de eerste fase van de ontsteking speelt de vorming van 
immuuncomplexen (complexen van antigeen met antigeen-specifieke 
antilichamen) een belangrijke rol, terwijl in latere fase specifieke T-lymfocyten 
de ontstekingsreactie versterken. Deze afweerreactie is erop gericht de 
ontstekingsprikkel op te ruimen, maar door bijkomende overmatige cytokine 
productie ontaart het proces in een ontsteking met alle negatieve gevolgen van 
dien (figuur 1). Deze ontsteking dooft na verloop van tijd uit, maar kan 
worden opgevlamd door een zeer kleine hoeveelheid van het antigeen in het 
hyperreactieve gewricht te spuiten. De ontsteking die ontstaat is kortdurend en 
met name T-lymfocyten zijn belangrijk. 
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antilichamen i = > aantrekken cellen, 
zoals: granulocyten 
monocyten 
macrofagen 
mestcellen 
lymfocyten 
n 
cytokines + enzymen 
n 
ontsteking 
kraakbeen schade 
Figuur 1. De rol van lymfocyten in een ontstekingsreactie en het ontstaan van 
weefselschade. 
Interventies met als doel de ontsteking te onderdrukken, kunnen erop gericht 
zijn om pro-inflammatoire cytokines weg te vangen, maar ook interventies op 
regulatoir nivo behoren tot de mogelijkheden. In deze studie zijn met name 
modulaties van T-cel immuniteit en achterliggende mechanismen bestudeerd. 
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T-lymfocyten kunnen op grond van specifieke oppervlakte receptoren 
onderverdeeld worden in twee subklasses ni. CD4+ (Thelper) en CD8+ 
(Tsuppressor) T-lymfocyten. Recente ontwikkelingen in de immunologie 
hebben aangetoond dat CD44 T-lymfocyten verder onderverdeeld kunnen 
worden in Thelper 1 (Thl) en Thelper 2 (Th2) lymfocyten. In het algemeen 
wordt verondersteld dat Thl cellen pro-inflammatoire cytokines produceren 
zoals interleukine-2 (IL-2) en interferon γ (IFNY), terwijl Th2 cellen anti-
infiammatoire cytokines zoals IL-4 en IL-10 produceren. Deze Thl en Th2 
cellen kunnen eikaars werking direct, maar ook via andere celtypen (zoals 
macrofagen) beïnvloeden (zie figuur 1 in de 'general introduction'). 
Voordat T-lymfocyten een respons kunnen ontwikkelen op een eiwit 
(antigeen), moet een eiwit eerst geknipt worden in kleine fragmenten 
(epitopen). Dit gebeurt door specifieke cellen, genaamd antigeen presenterende 
cellen (APC). In hoofdstuk 4 is gekeken naar de capaciteit van enzymen die 
voorkomen in speciale celcompartimenten (lysosomen/endosomen) van APC 
om een eiwit te knippen in T-cel stimulatoire epitopen. Het enzym cathepsine 
D bleek epitopen te kunnen genereren die in drie genetisch verschillende 
stammen muizen overeenkomstige T-cel responsen te zien gaven. Dit in 
tegenstelling tot andere studies waar gebruik werd gemaakt van relatief korte, 
chemisch gesynthetiseerde peptiden, en waar genetisch afhankelijke responsen 
gemeten werden. Onze resultaten impliceren dat verschillende genetische 
achtergronden wellicht minder bepalend zijn voor het al dan niet responderen 
op verschillende epitopen. 
Een bekende manier om de opbouw van de immuniteit te onderdrukken, is het 
toedienen van een antigeen in een oplosbare vorm (niet immunogeen) voordat 
geïmmuniseerd wordt (= aanbieden van een antigeen in immunogene vorm). 
Dit kan door orale, intraveneuze, of intraperitoneale toediening van een 
antigeen. Dit wordt tolerantie-inductie genoemd, en uit zich in een verlaging 
van de ontsteking (hoofdstuk 3, 5 en 6). Een andere methode om tolerantie te 
induceren is door muizen te behandelen met gefixeerde antigeen-specifieke 
lymfocyten afkomstig uit lymfeklieren van geïmmuniseerde donor muizen (T-
cel vaccinatie). Hierdoor ontwikkelt zich een respons tegen antigeen-specifieke 
receptoren (idiotypen) aanwezig op deze cellen (anti-idiotypische respons), met 
als gevolg een onderdrukte immuniteit (hoofdstuk 2). Tolerantie-inductie door 
intraveneuze en orale toediening van een antigeen, en het toepassen van T-cel 
vaccinatie bleken effectief te zijn in het onderdrukken van een ontsteking. 
Echter, niet alle typen antigenen waren in staat tolerantie te induceren. Met 
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name de gemodificeerde, kationische (positief geladen) antigenen, en 
lymfocyten gericht tegen deze eiwitantigenen waren nauwelijks in staat 
tolerantie te induceren. Dit impliceert dat het succes van immunomodulatie in 
beschreven diermodel, maar wellicht ook in humane chronische 
ontstekingsziekten, afhankelijk is van het type antigeen wat mogelijk de 
ontsteking opwekt. 
In hoofdstuk 5 en 6 zijn mogelijke mechanismen bestudeerd die ten grondslag 
kunnen liggen aan het onderdrukken van een artritis door intraveneuze 
toediening van het antigeen. Zowel de generatie van CD8+ Tsuppressor-cellen, 
als het aanzwengelen van CD4+ Th2 lymfocyten bleken niet verantwoordelijk 
te zijn voor het onderdrukken van een ontsteking. Tevens lukte het niet om 
een aspecifiek suppressie systeem te genereren. In deze vorm van suppressie, 
genaamd 'antigen-driven bystander suppression', wordt een immuniteit gericht 
tegen antigeen X onderdrukt door voorbehandeling met een irrelevant antigeen 
Y. Dit systeem is beschreven door anderen voor orale tolerantie, en werkt via 
de productie van suppressieve factoren zoals Transforming Growth Factor β 
(TGFjS). Dit systeem van tolerantie inductie creëert mogelijkheden in 
ziektebeelden waar het oorzakelijke auto-antigeen onbekend is of waar wellicht 
meerdere antigenen betrokken zijn, zoals bv. in RA. Echter, in onze 
intraveneus geïnduceerde tolerantie experimenten bleek alleen antigeen-
specifieke behandeling tolerantie te kunnen induceren. Het mechanisme wat in 
onze model studies een belangrijke rol lijkt te spelen is het anerg (functioneel 
inactief) worden van antigeen-specifieke CD4+ T-lymfocyten. Hierdoor kan 
geen specifieke respons op het antigeen op gang komen, met als gevolg een 
verlaagde ontsteking. 
Tot slot is de rol van de autocriene groeifactoren IL-2 en IL-4 bestudeerd in 
opvlammingsreacties (hoofdstuk 7). Deze cytokines werden geneutraliseerd 
door behandeling met monoclonale antilichamen in vivo. Resultaten laten zien 
dat zowel het uitschakelen van het pro-inflammatoire cytokine IL-2 (o.a. 
geproduceerd door Thl cellen) alsmede het uit literatuur genoemde anti-
inflammatoire cytokine IL-4 (geproduceerd door Th2 en mestcellen) leidt tot 
een verlaging van de opvlamming. Indien IL-2 of IL-4 additioneel en lokaal 
werden bijgespoten, bleek de opvlamming in beide gevallen te verergeren. 
Deze bevindingen laten zien dat cytokines dualistische effecten kunnen hebben. 
Voordat Th2 cel geproduceerde cytokines voor therapeutische doeleinden 
gebruikt kunnen worden, zullen allereerst meer studies uitgevoerd moeten 
worden. 
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STELLINGEN 
behorende bij het proefschrift 
Modulation of Τ cell immunity in murine arthritis 
/ 
Het bedrijven van wetenschappelijk onderzoek is een labyrint. Het is de kunst 
om gericht een uitgang te vinden, (elk proefschrift ?) 
II 
Met statistiek kun je alles bewijzen. Er zijn leugens, grove leugens en 
statistiek. (Disraeli) 
III 
De kans om een bepaalde immuunstatus succesvol te moduleren is afhankelijk 
van het type antigeen dat betrokken is. (ditproefschrift) 
IV 
Niet alleen de balans tussen immuniteit en tolerantie slaat wel eens door; ook 
het evenwicht tussen natuur(lijke) en economische belangen is soms ver te 
zoeken. 
V 
De manier waarop suppressie gegenereerd wordt (oraal of intraveneus) bepaalt 
mede welk mechanisme van tolerantie in gang gezet wordt, (dit proefschrift) 
VI 
Het ontdekken van nieuwe cytokines gaat 'allegretto' ; echter het begrijpen 
van regulatoire processen gaat 'multo andante'. 
VII 
Het bestuderen van facetten geeft helderheid en inzicht, maar de balans van 
het totaal bepaalt de uiteindelijke uitkomst. 
VIII 
De rol van IL-4 in een lysozym geïnduceerde arthritis is pro-intlammatoir. 
(dit proefschrift) 
IX 
Vraagstellingen in proefdieronderzoek gaan vaak een eigen leven leiden. Dit 
betekent lijden en geen leven voor het proefdier. 
X 
Leven is tekenen zonder gum. (Bond zonder Naam) 
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